Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 1993 - 1996
  • Medical Resident, Medicine, University of Washington 1990 - 1993
  • M.D., Yale University 1990
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2012
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2008
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2004
  • Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1996 - 1999
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1996
• Research
• 

  Selected Grants

  • SPICE-ColoAd1-1003 awarded by PsiOxus Therapeutics Ltd. 2018 - 2023
  • HIMALAYA awarded by AstraZeneca AB 2018 - 2023
  • HALO-110-101 awarded by Halozyme, Inc. 2018 - 2023
  • Eisai H3B-6527-G000-101 - 1012 awarded by H3 Biomedicine, Inc. 2018 - 2023
  • Treetop Aslan awarded by ASLAN Pharmaceuticals 2017 - 2022
  • Merck -VRP-HER2 vaccination awarded by Merck Sharp & Dohme 2018 - 2022
  • A Phase I dose escalation and cohort expansion study of ERY974 awarded by Chugai Pharmaceutical Company, Ltd. 2016 - 2021
  • Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
  • Phase Ib/II Study of Pembrolizumab with Lanreotide Depot (Planet)-Merck awarded by Merck 2017 - 2021
  • A Phase I study of Niclosamide in patients with resectable colon cancer. awarded by Bayer HealthCare AG 2015 - 2020
  • Characterization of Tumor Immunobiological Factors that Promote Lymphovascular Invasion and Dissemination in Locally Advanced Breast Cancer awarded by Department of Defense 2017 - 2020
  • A pilot study of active immunotherapy with CEA (6D) VRP vaccine (AVX701) in patients with stage III colon cancer. awarded by AlphaVax, Inc. 2013 - 2019
  • Phase Ib/II Study of Pembrolizumab with Lanreotide Depot (Planet) Ipsen Study Drug awarded by Ipsen Biopharmaceuticals, Inc. 2016 - 2019
  • A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or awarded by Bristol-Myers Squibb Company 2014 - 2019
  • A phase I/2 open label study of Nivolumab manotherapy or Nivolmab combined with ipilmujab in subjects with advanced or m awarded by Bristol-Myers Squibb Company 2013 - 2018
  • A multicenter rendomized open label phase 3 trial to compare the efficacy and safety of Lenvatinib versus Sorafenib in f awarded by Eisai, Inc. 2013 - 2018
  • Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy awarded by Department of Defense 2012 - 2018
  • Oncogenic Signaling Networks awarded by Department of Defense 2012 - 2018
  • UNC - Duke Immunotherapy Training Program awarded by University of North Carolina - Chapel Hill 2017 - 2018
  • A Phase III study of pemborlizumab (MK-3475) vs chemotherapy in microstatilitte instablility - High (MSI-H) or mismatch repair deficienct (dMMR) stage IV colorectal awarded by Merck Sharp & Dohme 2016 - 2018
  • A phase 2B randomized controlled multicenter open-label study of the efficacy and immune responsoe of GVAX pancreas vacc awarded by Aduro BioTech 2014 - 2018
  • Targeting the WNT/beta-catenin Pathway in Triple Negative Breast Cancer awarded by Department of Defense 2013 - 2018
  • An Open label single arm phase I study of the pahramcokinetics and safety of Carfilzomib in subjects with advanced malig awarded by Onyx Pharmaceuticals, Inc 2013 - 2018
  • Long term follow up of subject who participated in aduro sponsored protocols awarded by Aduro BioTech 2015 - 2017
  • Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy awarded by Department of Defense 2013 - 2017
  • A Phase 3 randomized placebo contolled parellel-group multicenter double blined study to evaluate the efficacy awarded by Lexicon Pharmaceuticals 2014 - 2015
  • Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo awarded by Department of Defense 2012 - 2015
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • Targeting hCG-beta for Breast Cancer Immunotherapy awarded by National Institutes of Health 2004 - 2009
  • Vaccination with Regulatory T Cell Depletion awarded by National Institutes of Health 2006 - 2008
  • Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
  • Immunotherapy using peptide MHC tetramer isolated Tcells awarded by National Institutes of Health 2002 - 2007
  • Dendritic Cell Mobilization and Active Immunotherapy awarded by National Institutes of Health 2001 - 2007
  • Planning a Duke Academic Public Private Partnership Program (AP4) Center awarded by National Cancer Institute 2004 - 2006
  • Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer awarded by Agency for Healthcare Research and Quality 2004 - 2005
  • Dexasome Based Immunotherapy of Lung Cancer awarded by National Institutes of Health 2001 - 2004
  • Immunotherapy with TRICOM Modified Dendritic Cells awarded by National Institutes of Health 2001 - 2003
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Morse, MA, and Llovet, JM. Emerging Therapies: Introduction. December 9, 2009.  Full Text

  • Book Sections

    • Doan, PL, Vauthey, JN, Palavecino, M, and Morse, MA. "Colorectal Liver Metastases." In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 342-346. December 9, 2009.  Full Text
    • Huitzil-Melendez, FD, Abou-Alfa, GK, and Morse, MA. "Novel Therapies Targeted at Signal Transduction in Liver Tumors." In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 382-392. December 9, 2009.  Full Text
    • Samaras, P, Morse, MA, and Pestalozzi, BC. "Systemic Treatment of Hepatobiliary Tumors." In Malignant Liver Tumors: Current and Emerging Therapies: Third Edition, 107-121. December 9, 2009.  Full Text
    • Hsu, DS, Morse, M, Clay, T, Devi, G, and Lyerly, HK. "Immune Cells and the Tumor Microenvironment." 818-829. 2009.  Full Text
    • Morse, M. "Foreword." January 1, 2008.
    • Morse, MA, Clay, TM, and Lyerly, HK. "Tumor antigens." In General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology, 17-31. January 1, 2008.  Full Text
    • Hobeika, AC, Morse, MA, Clay, TM, Osada, T, Mosca, PJ, and Lyerly, HK. "Intracellular Cytokine Assays." 336-340. 2005.  Full Text

  • Conference Papers

    • Devi, GR, Hwang, E-SS, Stewart, J, Morse, MA, and Laere, SV. "Abstract B44: Immune pathway dysregulations in inflammatory breast cancer health disparity." February 2017.  Full Text
    • Clark, J, Morse, MA, Wong, MK, McDermott, DF, Kaufman, H, Daniels, GA, Perritt, JC, Hua, H, and Aung, S. "Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2)." January 10, 2016.  Full Text
    • Clark, JI, Morse, MA, Wong, MKK, Mcdermott, DF, Kaufman, HL, Daniels, GA, Perritt, JC, Hua, H, and Aung, S. "Durability of responses in patients with metastatic renal cell carcinoma treated with high dose lnterleukin-2 (HD IL-2)." December 2015.  Link to Item
    • Antonia, SJ, Bendell, J, Taylor, M, Calvo, E, Jaeger, D, de Braud, F, Ott, PA, Pietanza, MC, Horn, L, Le, DT, Morse, MA, Lopez-Martin, JA, Ascierto, PA, Christensen, O, Grosso, JF, Simon, J, Lin, C, and Eder, JP. "Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032." October 2015.  Link to Item
    • Calvo, E, López-Martin, J, Bendell, J, Eder, J, Taylor, M, Ott, P, Pietanza, M, Horn, L, Jäger, D, Braud, FD, Morse, M, Ascierto, P, Le, D, Amin, A, Evans, J, Simon, J, Lin, C, Christensen, O, and Antonia, S. "3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)." September 2015.  Full Text
    • Aung, S, Morse, MA, Wong, MK, Kaufman, H, Daniels, GA, and McDermott, DF. "High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR)." March 2015.  Full Text
    • Duffy, AG, Beg, MS, Greten, TF, Beatson, MA, Mavroukakis, S, Patel, SP, Morse, MA, and Arlen, PM. "A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F)." January 20, 2015.  Full Text
    • Clark, JI, Wong, MK, Daniels, GA, Kaufman, HL, McDermott, DF, Morse, MA, and Aung, S. "Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era." October 2014.  Link to Item
    • Gabitzsch, ES, Morse, MA, Lyerly, HK, Balint, J, and Jones, F. "Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011." May 20, 2014.  Link to Item
    • Holcombe, RF, Xiu, J, Gatalica, Z, and Morse, MA. "Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options." May 20, 2014.  Link to Item
    • Gabitzsch, ES, Morse, MA, Lyerly, HK, and Jones, F. "Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic." April 15, 2013.  Full Text
    • Patel, SP, Morse, MA, Diaz, LA, Azad, NS, Haley, S, and Arlen, PM. "Abstract LB-161: A phase I safety study of NPC-1C, a novel, therapeutic antibody to treat pancreas and colorectal cancers." April 15, 2013.  Full Text
    • Smith, AD, Muir, AJ, Morse, MA, Suhocki, PV, and Ravindra, KV. "Liver Transplantation Following Down-Staging of a Large Primary Liver Tumor Associated with a Very High Serum Alpha Fetoprotein Concentration." June 2011.  Link to Item
    • Bullock, KE, Hurwitz, HI, Uronis, HE, Morse, MA, Blobe, GC, Hsu, SD, Zafar, SY, Nixon, AB, Howard, LA, and Bendell, JC. "Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)." May 20, 2009.  Link to Item
    • Clay, TM, Hobeika, A, Osada, T, Serra, D, Niedzwiecki, D, Lyerly, HK, and Morse, MA. "Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines." May 20, 2008.  Full Text  Link to Item
    • Uronis, HE, II, HJE, Coan, A, Bronson, K, Wheeler, J, Lyerly, HK, Morse, MA, and Abernethy, AP. "E/Tablets to collect research-quality, patient-reported data." May 20, 2008.  Full Text  Link to Item
    • Nelson, JW, Willett, CG, Clough, R, Clary, BM, Pappas, TN, Tyler, DS, Bendell, JC, Hurwitz, HI, Morse, MA, and Czito, BG. "Concurrent chemoradiation for resectable extrahepatic cholangiocarcinoma." 2007.  Full Text  Link to Item
    • Fisher, DA, Mantyh, CR, Morse, MA, Prosnitz, RG, Samsa, GR, and Patwardhan, MB. "Quality measures for colorectal cancer diagnosis: A systematic review." April 2006.  Link to Item
    • Nelson, JW, Kelsey, CR, Willett, CG, Tyler, DS, Pappas, TN, Hurwitz, HI, Bendell, JC, Morse, MA, Clough, R, and Czito, BG. "Adenocarcinoma of the duodenum: A 30-year experience." 2006.  Full Text  Link to Item
    • Cohn, A, Morse, MA, O'Neil, B, Bellgrau, D, Duke, RC, Franzusoff, AJ, Munson, S, Ferraro, J, and Rodell, TC. "Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial." June 1, 2005.  Link to Item
    • Richards, JM, Bedikian, A, Gonzalez, R, Atkins, MB, Whitman, E, Lutzky, J, Morse, MA, Amatruda, T, Galanis, E, Thompson, J, and Team, VCRO. "High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial." June 1, 2005.  Link to Item
    • Chui, SY, Morse, MA, Doldo, T, Osada, T, Clay, TM, Lyerly, HK, Khan, S, Gattis, A, and Hobeika, AC. "Regulatory and effector T cell subsets and dendritic cells in breast cancer." July 15, 2004.  Link to Item
    • Ishioka, GY, Disis, ML, Morse, MA, Cunningham, CC, Lenz, HJ, Figlin, RA, Chesnut, RW, and Fikes, J. "A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients." July 15, 2004.  Link to Item
    • Richards, J, Bedikian, AY, Gonzalez, R, Atkins, MB, Whitman, ED, Lutzky, J, Morse, MA, Amatruda, T, and Galanis, E. "A phase 2 trial of high-dose allovectin-7 in patients with advanced metastatic melanoma." July 15, 2004.  Link to Item
    • Cheng, TY, White, R, Ueno, T, Hurwitz, HI, Morse, MA, Czito, B, Clary, BM, Pappas, TN, and Tyler, DS. "Effects of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy." February 2004.  Full Text  Link to Item
    • Osada, T, Morse, MA, Clay, TM, Shimosaka, A, and Lyerly, HK. "Suppression of antigen-specific CTL generation by human NKT cell secretion of TH2 cytokines." April 14, 2003.  Link to Item
    • Venturi, CB, Osada, T, Serraz, D, Hartman, Z, Evelyn, C, Morse, MA, Clay, TM, Amalfitano, A, and Lyerly, HK. "Comparison of antigen-specific T cell responses induced by transduction of human dendritic cells with E1- and E1-, E2b- adenoviral vectors: Development of adenovirus vectors for DC-based anti-tumor immunotherapy." April 14, 2003.  Link to Item
    • White, R, Xie, HB, Gottfried, MR, Czito, BG, Hurwitz, HI, Morse, MA, Paulson, EK, Jowell, PS, Baillie, J, Branch, MS, Clary, BM, Pappas, TN, and Tyler, DS. "Prognostic significance of histologic response to preoperative chemoradiation for periampullary tumors." January 2003.  Link to Item
    • Colling, KL, Hobeika, AC, Mosca, PJ, Clay, TM, Lyerly, HK, and Morse, MA. "Enumerating functionally mature monocyte-derived dendritic cells for use in cancer immunotherapy." November 16, 2001.  Link to Item
    • Hobeika, AC, Peplinski, S, Morse, MA, Mosca, PJ, Clay, TC, and Lyerly, HK. "Quantitating antigen specific T cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot and intracellular cytokine analysis." November 16, 2001.  Link to Item
    • Morse, MA, Rizzieri, D, Hobeika, AC, Chao, N, and Lyerly, HK. "Dendritic cell (DC) reconstitution after non-myeloablative allogeneic stem cell transplants." November 16, 2000.  Link to Item
    • Mosca, PJ, Hobeika, AC, Clay, TM, Nair, SK, Thomas, EK, Caron, DA, Lyerly, HK, and Morse, MA. "Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells." November 16, 2000.  Link to Item
    • Morse, MA, Rizzieri, D, Hobeika, AC, Chao, N, and Lyerly, HK. "Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants." 2000.

  • Journal Articles

    • Jia, J, Morse, MA, Nagy, RJ, Lanman, RB, and Strickler, JH. "Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer." Frontiers in Oncology 8 (August 28, 2018). (Academic Article)  Full Text  Link to Item
    • Osada, T, Hartman, ZC, Wei, J, Lei, G, Hobeika, AC, Gwin, WR, Diniz, MA, Spector, N, Clay, TM, Chen, W, Morse, MA, and Lyerly, HK. "Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers." Breast Cancer Research : Bcr 20, no. 1 (August 9, 2018): 90-null.  Full Text
    • Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.  Full Text
    • Kane, A, Thorpe, MP, Oldan, JD, Howard, BA, Zhu, J, Morse, MA, Wong, T, Petry, NA, Reiman, R, and Borges-Neto, S. "Predictors of survival in 211 patients with stage IV pulmonary and gastroenteropancreatic mIBG positive neuroendocrine tumors treated with I-131 mIBG." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine (May 18, 2018).  Full Text  Open Access Copy
    • Chino, F, Stephens, SJ, Choi, SS, Marin, D, Kim, CY, Morse, MA, Godfrey, DJ, Czito, BG, Willett, CG, and Palta, M. "The role of external beam radiotherapy in the treatment of hepatocellular cancer." Cancer (April 12, 2018). (Review)  Full Text
    • Cohn, A, Morse, MA, O'Neil, B, Whiting, S, Coeshott, C, Ferraro, J, Bellgrau, D, Apelian, D, and Rodell, TC. "Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial." Journal of Immunotherapy (Hagerstown, Md. : 1997) 41, no. 3 (April 2018): 141-150.  Full Text
    • Evans, MK, Brown, MC, Geradts, J, Bao, X, Robinson, TJ, Jolly, MK, Vermeulen, PB, Palmer, GM, Gromeier, M, Levine, H, Morse, MA, Van Laere, SJ, and Devi, GR. "XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype." Cancer Research 78, no. 7 (April 2018): 1726-1738.  Full Text
    • Overman, MJ, Lonardi, S, Wong, KYM, Lenz, H-J, Gelsomino, F, Aglietta, M, Morse, MA, Van Cutsem, E, McDermott, R, Hill, A, Sawyer, MB, Hendlisz, A, Neyns, B, Svrcek, M, Moss, RA, Ledeine, J-M, Cao, ZA, Kamble, S, Kopetz, S, and André, T. "Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 8 (March 2018): 773-779.  Full Text
    • Zhou, X, Qiao, G, Wang, X, Song, Q, Morse, MA, Hobeika, A, Gwin, WR, Ren, J, and Lyerly, HK. "CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine." Cancer chemotherapy and pharmacology 81, no. 2 (February 2018): 365-372.  Full Text
    • Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, C-X, Agarwal, P, Korman, AJ, Morse, MA, Gouin, K, Knott, SRV, Lyerly, HK, and Hartman, ZC. "Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors." Oncoimmunology 7, no. 5 (January 19, 2018): e1421891-null.  Full Text
    • Curti, B, Daniels, GA, McDermott, DF, Clark, JI, Kaufman, HL, Logan, TF, Singh, J, Kaur, M, Luna, TL, Gregory, N, Morse, MA, Wong, MKK, and Dutcher, JP. "Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry." Journal for Immunotherapy of Cancer 5, no. 1 (December 19, 2017): 102-null.  Full Text
    • Osada, T, Kaneko, K, Gwin, WR, Morse, MA, Hobeika, A, Pogue, BW, Hartman, ZC, Hughes, PF, Haystead, T, and Lyerly, HK. "In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7531-7542.  Full Text
    • Le, DT, Hubbard-Lucey, VM, Morse, MA, Heery, CR, Dwyer, A, Marsilje, TH, Brodsky, AN, Chan, E, Deming, DA, Diaz, LA, Fridman, WH, Goldberg, RM, Hamilton, SR, Housseau, F, Jaffee, EM, Kang, SP, Krishnamurthi, SS, Lieu, CH, Messersmith, W, Sears, CL, Segal, NH, Yang, A, Moss, RA, Cha, E, O'Donnell-Tormey, J, Roach, N, Davis, AQ, McAbee, K, Worrall, S, and Benson, AB. "A Blueprint to Advance Colorectal Cancer Immunotherapies." Cancer Immunology Research 5, no. 11 (November 2017): 942-949.  Full Text
    • Jiang, N, Qiao, G, Wang, X, Morse, MA, Gwin, WR, Zhou, L, Song, Y, Zhao, Y, Chen, F, Zhou, X, Huang, L, Hobeika, A, Yi, X, Xia, X, Guan, Y, Song, J, Ren, J, and Lyerly, HK. "Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 17 (September 2017): 5066-5073.  Full Text
    • Overman, MJ, McDermott, R, Leach, JL, Lonardi, S, Lenz, H-J, Morse, MA, Desai, J, Hill, A, Axelson, M, Moss, RA, Goldberg, MV, Cao, ZA, Ledeine, J-M, Maglinte, GA, Kopetz, S, and André, T. "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study." The Lancet. Oncology 18, no. 9 (September 2017): 1182-1191.  Full Text
    • Riedel, RF, Meadows, KL, Lee, PH, Morse, MA, Uronis, HE, Blobe, GC, George, DJ, Crawford, J, Niedzwiecki, D, Rushing, CN, Arrowood, CC, and Hurwitz, HI. "Phase I study of pazopanib plus TH-302 in advanced solid tumors." Cancer chemotherapy and pharmacology 79, no. 3 (March 2017): 611-619.  Full Text
    • Clark, JI, Wong, MKK, Kaufman, HL, Daniels, GA, Morse, MA, McDermott, DF, Agarwala, SS, Lewis, LD, Stewart, JH, Vaishampayan, U, Curti, B, Gonzalez, R, Lutzky, J, Rudraptna, V, Cranmer, LD, Jeter, JM, Hauke, RJ, Miletello, G, Milhem, MM, Amin, A, Richart, JM, Fishman, M, Hallmeyer, S, Patel, SP, Van Veldhuizen, P, Agarwal, N, Taback, B, Treisman, JS, Ernstoff, MS, Perritt, JC, Hua, H, Rao, TB, Dutcher, JP, and Aung, S. "Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM." Clinical Genitourinary Cancer 15, no. 1 (February 2017): 31-41.e4.  Full Text
    • Osada, T, Morse, MA, Hobeika, A, Diniz, MA, Gwin, WR, Hartman, Z, Wei, J, Guo, H, Yang, X-Y, Liu, C-X, Kaneko, K, Broadwater, G, and Lyerly, HK. "Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition." Oncoimmunology 6, no. 6 (January 2017): e1315495-null.  Full Text
    • Ren, J, Gwin, WR, Zhou, X, Wang, X, Huang, H, Jiang, N, Zhou, L, Agarwal, P, Hobeika, A, Crosby, E, Hartman, ZC, Morse, MA, H Eng, K, and Lyerly, HK. "Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy." Oncoimmunology 6, no. 4 (January 2017): e1264563-null.  Full Text
    • Alva, A, Daniels, GA, Wong, MKK, Kaufman, HL, Morse, MA, McDermott, DF, Clark, JI, Agarwala, SS, Miletello, G, Logan, TF, Hauke, RJ, Curti, B, Kirkwood, JM, Gonzalez, R, Amin, A, Fishman, M, Agarwal, N, Lowder, JN, Hua, H, Aung, S, and Dutcher, JP. "Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma." Cancer Immunology, Immunotherapy : Cii 65, no. 12 (December 2016): 1533-1544.  Full Text
    • Langman, EL, Suhocki, PV, Hurwitz, HI, Morse, MA, Burbridge, RA, Smith, TP, and Kim, CY. "Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden." Journal of gastrointestinal oncology 7, no. 6 (December 2016): 875-881.  Full Text
    • Pishvaian, M, Morse, MA, McDevitt, J, Norton, JD, Ren, S, Robbie, GJ, Ryan, PC, Soukharev, S, Bao, H, and Denlinger, CS. "Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas." Clinical Colorectal Cancer 15, no. 4 (December 2016): 345-351.  Full Text
    • Pishvaian, M, Morse, MA, McDevitt, J, Norton, JD, Ren, S, Robbie, GJ, Ryan, PC, Soukharev, S, Bao, H, and Denlinger, CS. "Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas." Clinical Colorectal Cancer 15, no. 4 (December 2016): 345-351.  Full Text  Link to Item
    • Sharma, P, Callahan, MK, Bono, P, Kim, J, Spiliopoulou, P, Calvo, E, Pillai, RN, Ott, PA, de Braud, F, Morse, M, Le, DT, Jaeger, D, Chan, E, Harbison, C, Lin, C-S, Tschaika, M, Azrilevich, A, and Rosenberg, JE. "Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial." The Lancet. Oncology 17, no. 11 (November 2016): 1590-1598.  Full Text
    • Beg, MS, Azad, NS, Patel, SP, Torrealba, J, Mavroukakis, S, Beatson, MA, Wang, XP, Arlen, PM, and Morse, MA. "A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer." Cancer Chemotherapy and Pharmacology 78, no. 3 (September 2016): 577-584.  Full Text
    • Quiroga, D, Lyerly, HK, and Morse, MA. "Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer." Current treatment options in oncology 17, no. 8 (August 2016): 41-. (Review)  Full Text
    • Antonia, SJ, López-Martin, JA, Bendell, J, Ott, PA, Taylor, M, Eder, JP, Jäger, D, Pietanza, MC, Le, DT, de Braud, F, Morse, MA, Ascierto, PA, Horn, L, Amin, A, Pillai, RN, Evans, J, Chau, I, Bono, P, Atmaca, A, Sharma, P, Harbison, CT, Lin, C-S, Christensen, O, and Calvo, E. "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial." The Lancet. Oncology 17, no. 7 (July 2016): 883-895.  Full Text
    • Morse, MA. "Immunotherapy for Resected Pulmonary Metastases." Thoracic surgery clinics 26, no. 1 (February 2016): 69-78. (Review)  Full Text
    • Morse, MA. "The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer." Current Colorectal Cancer Reports 12, no. 1 (February 2016): 51-56.  Full Text
    • Evans, MK, Sauer, SJ, Nath, S, Robinson, TJ, Morse, MA, and Devi, GR. "X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity." Cell Death & Disease 7 (January 28, 2016): e2073-null.  Full Text  Open Access Copy
    • Buchbinder, EI, Gunturi, A, Perritt, J, Dutcher, J, Aung, S, Kaufman, HL, Ernstoff, MS, Miletello, GP, Curti, BD, Daniels, GA, Patel, SP, Kirkwood, JM, Hallmeyer, S, Clark, JI, Gonzalez, R, Richart, JM, Lutzky, J, Morse, MA, Sullivan, RJ, and McDermott, DF. "A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma." Journal for Immunotherapy of Cancer 4 (January 2016): 52-null.  Full Text
    • Roe, MT, Cyr, DD, Eckart, D, Schulte, PJ, Morse, MA, Blackwell, KL, Ready, NE, Zafar, SY, Beaven, AW, Strickler, JH, Onken, JE, Winters, KJ, Houterloot, L, Zamoryakhin, D, Wiviott, SD, White, HD, Prabhakaran, D, Fox, KAA, Armstrong, PW, Ohman, EM, and TRILOGY ACS Investigators, . "Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." European Heart Journal 37, no. 4 (January 2016): 412-422.  Full Text
    • Wong, MK, Morse, MA, McDermott, DF, Clark, JI, Kaufman, HL, Daniels, GA, Hua, H, and Aung, S. "Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2." Cancer Immunology Research 4, no. 1 Supplement (January 2016): B140-B140.  Full Text
    • Morse, MA, and Lyerly, HK. "Checkpoint blockade in combination with cancer vaccines." Vaccine 33, no. 51 (December 2015): 7377-7385. (Review)  Full Text
    • Ren, XR, Wang, J, Osada, T, Mook, RA, Morse, MA, Barak, LS, Lyerly, HK, and Chen, W. "Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth." Breast cancer research : BCR 17, no. 1 (December 2015): 528-.
    • Song, Q-K, Ren, J, Zhou, X-N, Wang, X-L, Song, G-H, Di, L-J, Yu, J, Hobeika, A, Morse, MA, Yuan, Y-H, Yang, H-B, and Lyerly, HK. "The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion." Oncotarget 6, no. 38 (December 2015): 41350-41359.  Full Text
    • Calvo, E, Lopez-Martin, J, Bendell, J, Eder, JP, Taylor, M, Ott, PA, Pietanza, MC, Horn, L, Jaeger, D, de Braud, F, Morse, MA, Ascierto, PA, Le, DT, Amin, A, Evans, J, Simon, JS, Lin, C-S, Christensen, O, and Antonia, SJ. "NIVOLUMAB (NIVO) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB (IPI) FOR TREATMENT OF RECURRENT SMALL CELL LUNG CANCER (SCLC)." Asia-Pacific Journal of Clinical Oncology 11 (November 2015): 118-118.  Link to Item
    • Balint, JP, Gabitzsch, ES, Rice, A, Latchman, Y, Xu, Y, Messerschmidt, GL, Chaudhry, A, Morse, MA, and Jones, FR. "Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer." Cancer Immunology, Immunotherapy 64, no. 8 (August 28, 2015): 977-987.  Full Text
    • Balint, JP, Gabitzsch, ES, Rice, A, Latchman, Y, Xu, Y, Messerschmidt, GL, Chaudhry, A, Morse, MA, and Jones, FR. "Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer." Cancer immunology, immunotherapy : CII 64, no. 8 (August 2015): 977-987.  Full Text
    • Berinstein, NL, Karkada, M, Oza, AM, Odunsi, K, Villella, JA, Nemunaitis, JJ, Morse, MA, Pejovic, T, Bentley, J, Buyse, M, Nigam, R, Weir, GM, MacDonald, LD, Quinton, T, Rajagopalan, R, Sharp, K, Penwell, A, Sammatur, L, Burzykowski, T, Stanford, MM, and Mansour, M. "Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients." Oncoimmunology 4, no. 8 (August 2015): e1026529-null.  Full Text
    • Osada, T, Patel, SP, Hammond, SA, Osada, K, Morse, MA, and Lyerly, HK. "CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1." Cancer Immunology, Immunotherapy : Cii 64, no. 6 (June 2015): 677-688.  Full Text
    • Osada, T, Nagaoka, K, Takahara, M, Yang, XY, Liu, C-X, Guo, H, Roy Choudhury, K, Hobeika, A, Hartman, Z, Morse, MA, and Lyerly, HK. "Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors." Journal of immunotherapy (Hagerstown, Md. : 1997) 38, no. 4 (May 2015): 155-164.  Full Text
    • Le, DT, Wang-Gillam, A, Picozzi, V, Greten, TF, Crocenzi, T, Springett, G, Morse, M, Zeh, H, Cohen, D, Fine, RL, Onners, B, Uram, JN, Laheru, DA, Lutz, ER, Solt, S, Murphy, AL, Skoble, J, Lemmens, E, Grous, J, Dubensky, T, Brockstedt, DG, and Jaffee, EM. "Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer." Journal of Clinical Oncology 33, no. 12 (April 2015): 1325-1333.  Full Text
    • Ren, X-R, Wang, J, Osada, T, Mook, RA, Morse, MA, Barak, LS, Lyerly, HK, and Chen, W. "Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth." Breast cancer research : BCR 17 (February 15, 2015): 20-.  Full Text
    • Maier, S, Chung, CH, Morse, M, Platts-Mills, T, Townes, L, Mukhopadhyay, P, Bhagavatheeswaran, P, Racenberg, J, and Trifan, OC. "A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions." Cancer medicine 4, no. 1 (January 2015): 36-42.  Full Text
    • Wolin, EM, Jarzab, B, Eriksson, B, Walter, T, Toumpanakis, C, Morse, MA, Tomassetti, P, Weber, MM, Fogelman, DR, Ramage, J, Poon, D, Gadbaw, B, Li, J, Pasieka, JL, Mahamat, A, Swahn, F, Newell-Price, J, Mansoor, W, and Öberg, K. "Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues." Drug Design, Development and Therapy 9 (January 2015): 5075-5086.  Full Text
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of Surgical Oncology 21, no. 8 (August 2014): 2525-2531.  Full Text
    • Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational new drugs 32, no. 4 (August 2014): 700-709.  Full Text
    • Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Invest New Drugs 32, no. 2 (April 2014): 330-339.  Full Text  Link to Item
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of Surgical Oncology 21, no. 8 (January 1, 2014): 2525-2531.  Full Text
    • Kaufman, HL, Wong, MK, Daniels, GA, McDermott, DF, Aung, S, Lowder, JN, and Morse, MA. "The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)." Journal of personalized medicine 4, no. 1 (January 2014): 52-64.  Full Text
    • Patel, SP, Osada, T, Lyerly, HK, and Morse, MA. "Designing effective vaccines for colorectal cancer." Immunotherapy 6, no. 8 (January 2014): 913-926. (Review)  Full Text
    • Rangwala, F, Bendell, JC, Kozloff, MF, Arrowood, CC, Dellinger, A, Meadows, J, Tourt-Uhlig, S, Murphy, J, Meadows, KL, Starr, A, Broderick, S, Brady, JC, Cushman, SM, Morse, MA, Uronis, HE, Hsu, SD, Zafar, SY, Wallace, J, Starodub, AN, Strickler, JH, Pang, H, Nixon, AB, and Hurwitz, HI. "Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors." Investigational New Drugs 32, no. 4 (January 1, 2014): 700-709.  Full Text
    • Strickler, JH, McCall, S, Nixon, AB, Brady, JC, Pang, H, Rushing, C, Cohn, A, Starodub, A, Arrowood, C, Haley, S, Meadows, KL, Morse, MA, Uronis, HE, Blobe, GC, Hsu, SD, Zafar, SY, and Hurwitz, HI. "Phase i study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer." Investigational New Drugs 32, no. 2 (January 1, 2014): 330-339.  Full Text
    • Turaga, K, Levine, E, Barone, R, Sticca, R, Petrelli, N, Lambert, L, Nash, G, Morse, M, Adbel-Misih, R, Alexander, HR, Attiyeh, F, Bartlett, D, Bastidas, A, Blazer, T, Chu, Q, Chung, K, Dominguez-Parra, L, Espat, NJ, Foster, J, Fournier, K, Garcia, R, Goodman, M, Hanna, N, Harrison, L, Hoefer, R, Holtzman, M, Kane, J, Labow, D, Li, B, Lowy, A, Mansfield, P, Ong, E, Pameijer, C, Pingpank, J, Quinones, M, Royal, R, Salti, G, Sardi, A, Shen, P, Skitzki, J, Spellman, J, Stewart, J, and Esquivel, J. "Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States." Annals of Surgical Oncology 21, no. 5 (2014): 1501-1505.  Full Text
    • Wong, MK, Kaufman, HL, Daniels, GA, McDermott, DF, Aung, S, Lowder, JN, and Morse, MA. "Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes." Journal for Immunotherapy of Cancer 2 (January 2014): 20-null.  Full Text
    • Morse, MA, Niedzwiecki, D, Marshall, JL, Garrett, C, Chang, DZ, Aklilu, M, Crocenzi, TS, Cole, DJ, Dessureault, S, Hobeika, AC, Osada, T, Onaitis, M, Clary, BM, Hsu, D, Devi, GR, Bulusu, A, Annechiarico, RP, Chadaram, V, Clay, TM, and Lyerly, HK. "A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer." Annals of Surgery 258, no. 6 (December 1, 2013): 879-886.  Full Text
    • Morse, MA, Niedzwiecki, D, Marshall, JL, Garrett, C, Chang, DZ, Aklilu, M, Crocenzi, TS, Cole, DJ, Dessureault, S, Hobeika, AC, Osada, T, Onaitis, M, Clary, BM, Hsu, D, Devi, GR, Bulusu, A, Annechiarico, RP, Chadaram, V, Clay, TM, and Lyerly, HK. "A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer." Annals of Surgery 258, no. 6 (December 2013): 879-886.  Full Text
    • Patel, SP, Osada, T, Osada, K, Hurwitz, H, Lyerly, HK, and Morse, MA. "Modulation of immune system inhibitory checkpoints in colorectal cancer." Current Colorectal Cancer Reports 9, no. 4 (December 1, 2013): 391-397.  Full Text
    • Meadows, KL, Lee, PH, Riedel, RF, Morse, MA, Uronis, HE, Blobe, GC, George, DJ, Crawford, J, and Hurwitz, HI. "Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302." Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C61-C61.  Full Text
    • Karabudak, AA, Hafner, J, Shetty, V, Chen, S, Secord, AA, Morse, MA, and Philip, R. "Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels." Journal of Cancer Research and Clinical Oncology 139, no. 10 (October 2013): 1757-1770.  Full Text
    • Hanks, BA, Holtzhausen, A, Evans, KS, Jamieson, R, Gimpel, P, Campbell, OM, Hector-Greene, M, Sun, L, Tewari, A, George, A, Starr, M, Nixon, A, Augustine, C, Beasley, G, Tyler, DS, Osada, T, Morse, MA, Ling, L, Lyerly, HK, and Blobe, GC. "Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment." J Clin Invest 123, no. 9 (September 2013): 3925-3940.  Full Text  Open Access Copy  Link to Item
    • Morse, MA, Chaudhry, A, Gabitzsch, ES, Hobeika, AC, Osada, T, Clay, TM, Amalfitano, A, Burnett, BK, Devi, GR, Hsu, DS, Xu, Y, Balcaitis, S, Dua, R, Nguyen, S, Balint, JP, Jones, FR, and Lyerly, HK. "Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients." Cancer Immunology, Immunotherapy : Cii 62, no. 8 (August 2013): 1293-1301.  Full Text
    • Patel, SP, Bristol, A, Saric, O, Wang, X-P, Dubeykovskiy, A, Arlen, PM, and Morse, MA. "Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models." Cancer Immunology, Immunotherapy : Cii 62, no. 6 (June 2013): 1011-1019.  Full Text
    • Uronis, HE, Cushman, SM, Bendell, JC, Blobe, GC, Morse, MA, Nixon, AB, Dellinger, A, Starr, MD, Li, H, Meadows, K, Gockerman, J, Pang, H, and Hurwitz, HI. "A phase I study of ABT-510 plus bevacizumab in advanced solid tumors." Cancer Med 2, no. 3 (June 2013): 316-324.  Full Text  Open Access Copy  Link to Item
    • Aggarwal, C, Meropol, NJ, Punt, CJ, Iannotti, N, Saidman, BH, Sabbath, KD, Gabrail, NY, Picus, J, Morse, MA, Mitchell, E, Miller, MC, and Cohen, SJ. "Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 24, no. 2 (February 2013): 420-428.  Full Text
    • Allensworth, JL, Sauer, SJ, Lyerly, HK, Morse, MA, and Devi, GR. "Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism." Breast Cancer Research and Treatment 137, no. 2 (January 2013): 359-371.  Full Text  Open Access Copy
    • Allensworth, JL, Sauer, SJ, Lyerly, HK, Morse, MA, and Devi, GR. "Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism." Breast Cancer Research and Treatment 137, no. 2 (2013): 359-371.  Full Text
    • Karabudak, AA, Hafner, J, Shetty, V, Chen, S, Secord, AA, Morse, MA, and Philip, R. "Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels." Journal of Cancer Research and Clinical Oncology 139, no. 10 (2013): 1757-1770.  Full Text
    • Morse, MA, Chaudhry, A, Gabitzsch, ES, Hobeika, AC, Osada, T, Clay, TM, Amalfitano, A, Burnett, BK, Devi, GR, Hsu, DS, Xu, Y, Balcaitis, S, Dua, R, Nguyen, S, Jr, JPB, Jones, FR, and Lyerly, HK. "Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients." Cancer Immunology, Immunotherapy 62, no. 8 (2013): 1293-1301.  Full Text
    • Morse, MA, Gabitzsch, ES, Xu, Y, Rajesh, D, Nguyen, S, Balcaitis, S, Balint, JP, and Jones, F. "Abstract A29: An Ad5 [E1-, E2b-] platform carrying the TAA CEA(6D) induces CEA directed CMI responses in patients with advanced CEA-expressing colorectal cancer in a phase I/II clinical trial." Cancer Research 73, no. 1 Supplement (January 1, 2013): A29-A29.  Full Text
    • Morse, MA, Osada, T, Hobeika, A, Patel, S, and Lyerly, HK. "Biomarkers and correlative endpoints for immunotherapy trials." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting (January 2013). (Review)  Full Text
    • Nair, S, Aldrich, AJ, McDonnell, E, Cheng, Q, Aggarwal, A, Patel, P, Williams, MM, Boczkowski, D, Lyerly, HK, Morse, MA, and Devi, GR. "Immunologic targeting of FOXP3 in inflammatory breast cancer cells." PLoS One 8, no. 1 (2013): e53150-.  Full Text  Link to Item
    • Patel, SP, Osada, T, Osada, K, Hurwitz, H, Lyerly, HK, and Morse, MA. "Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer." Current Colorectal Cancer Reports (2013): 1-7.  Full Text
    • Turaga, K, Levine, E, Barone, R, Sticca, R, Petrelli, N, Lambert, L, Nash, G, Morse, M, Adbel-Misih, R, Alexander, HR, Attiyeh, F, Bartlett, D, Bastidas, A, Blazer, T, Chu, Q, Chung, K, Dominguez-Parra, L, Espat, NJ, Foster, J, Fournier, K, Garcia, R, Goodman, M, Hanna, N, Harrison, L, Hoefer, R, Holtzman, M, Kane, J, Labow, D, Li, B, Lowy, A, Mansfield, P, Ong, E, Pameijer, C, Pingpank, J, Quinones, M, Royal, R, Salti, G, Sardi, A, Shen, P, Skitzki, J, Spellman, J, Stewart, J, and Esquivel, J. "Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States." Annals of Surgical Oncology (2013): 1-5.  Full Text
    • Uronis, HE, Bendell, JC, Altomare, I, Blobe, GC, Hsu, SD, Morse, MA, Pang, H, Zafar, SY, Conkling, P, Favaro, J, Arrowood, CC, Cushman, SM, Meadows, KL, Brady, JC, Nixon, AB, and Hurwitz, HI. "A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." The Oncologist 18, no. 3 (January 2013): 271-272.  Full Text
    • Osada, T, Berglund, P, Morse, MA, Hubby, B, Lewis, W, Niedzwiecki, D, Yang, XY, Hobeika, A, Burnett, B, Devi, GR, Clay, TM, Smith, J, and Kim Lyerly, H. "Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects." Cancer Immunol Immunother 61, no. 11 (November 2012): 1941-1951.  Full Text  Link to Item
    • Morse, MA, Hanks, BA, Suhocki, P, Doan, PL, Liu, EA, Frost, P, Bernard, SA, Tsai, A, Moore, DT, and O'Neil, BH. "Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma." Clinical Colorectal Cancer 11, no. 3 (September 2012): 185-190.  Full Text
    • Berinstein, NL, Karkada, M, Morse, MA, Nemunaitis, JJ, Chatta, G, Kaufman, H, Odunsi, K, Nigam, R, Sammatur, L, MacDonald, LD, Weir, GM, Stanford, MM, and Mansour, M. "First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients." Journal of Translational Medicine 10 (August 3, 2012): 156-null.  Full Text
    • Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251-258.  Full Text  Link to Item
    • Kim, MK, Osada, T, Barry, WT, Yang, XY, Freedman, JA, Tsamis, KA, Datto, M, Clary, BM, Clay, T, Morse, MA, Febbo, PG, Lyerly, HK, and Hsu, DS. "Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer." Molecular Cancer Therapeutics 11, no. 7 (July 2012): 1500-1509.  Full Text
    • Vlahovic, G, Meadows, KL, Uronis, HE, Morse, MA, Blobe, GC, Riedel, RF, Zafar, SY, Alvarez-Secord, A, Gockerman, J, Starodub, AN, Ready, NE, Anderson, EL, Bendell, JC, and Hurwitz, HI. "A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors." Cancer Chemotherapy and Pharmacology 70, no. 1 (July 2012): 95-102.  Full Text
    • Ren, X-R, Wei, J, Lei, G, Wang, J, Lu, J, Xia, W, Spector, N, Barak, LS, Clay, TM, Osada, T, Hamilton, E, Blackwell, K, Hobeika, AC, Morse, MA, Lyerly, HK, and Chen, W. "Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. (Published online)" Breast Cancer Res 14, no. 3 (June 7, 2012): R89-.  Full Text  Link to Item
    • Osada, T, Morse, MA, Hobeika, A, and Lyerly, HK. "Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy." Semin Oncol 39, no. 3 (June 2012): 305-310. (Review)  Full Text  Link to Item
    • Morse, MA, Hobeika, A, Serra, D, Aird, K, McKinney, M, Aldrich, A, Clay, T, Mourich, D, Lyerly, HK, Iversen, PL, and Devi, GR. "Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function." Cancer Gene Ther 19, no. 1 (January 2012): 30-37.  Full Text  Link to Item
    • Rangwala, F, Williams, KP, Smith, GR, Thomas, Z, Allensworth, JL, Lyerly, HK, Diehl, AM, Morse, MA, and Devi, GR. "Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines." Bmc Cancer 12 (January 2012): 402-null.  Full Text
    • Uronis, JM, Osada, T, McCall, S, Yang, XY, Mantyh, C, Morse, MA, Lyerly, HK, Clary, BM, and Hsu, DS. "Histological and molecular evaluation of patient-derived colorectal cancer explants." Plos One 7, no. 6 (January 2012): e38422-null.  Full Text
    • Wong, NS, and Morse, MA. "Lonafarnib for cancer and progeria." Expert Opinion on Investigational Drugs 21, no. 7 (2012): 1043-1055.  Full Text
    • Hamilton, E, Hobeika, A, Lyerly, H, Owzar, K, Rocha, G, Kimmick, G, Marcom, P, Peppercorn, J, Morse, M, and Blackwell, K. "P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells." Cancer Research 71, no. 24 Supplement (December 15, 2011): P1-13-03-P1-13-03.  Full Text
    • Pruitt, SK, Boczkowski, D, de Rosa, N, Haley, NR, Morse, MA, Tyler, DS, Dannull, J, and Nair, S. "Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells." Eur J Immunol 41, no. 12 (December 2011): 3553-3563.  Full Text  Link to Item
    • Ghafoori, AP, Nelson, JW, Willett, CG, Chino, J, Tyler, DS, Hurwitz, HI, Uronis, HE, Morse, MA, Clough, RW, and Czito, BG. "Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma." Int J Radiat Oncol Biol Phys 81, no. 3 (November 1, 2011): 654-659.  Full Text  Link to Item
    • Hartman, ZC, Wei, J, Glass, OK, Guo, H, Lei, G, Yang, X-Y, Osada, T, Hobeika, A, Delcayre, A, Le Pecq, J-B, Morse, MA, Clay, TM, and Lyerly, HK. "Increasing vaccine potency through exosome antigen targeting." Vaccine 29, no. 50 (November 2011): 9361-9367.  Full Text
    • Wong, NS, Meadows, KL, Rosen, LS, Adjei, AA, Kaufmann, SH, Morse, MA, Petros, WP, Zhu, Y, Statkevich, P, Cutler, DL, Meyers, ML, and Hurwitz, HI. "A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer." Cancer Invest 29, no. 9 (November 2011): 617-625.  Full Text  Link to Item
    • Pruitt, SK, Boczkowski, D, de Rosa, N, Haley, NR, Morse, MA, Tyler, DS, Dannull, J, and Nair, S. "Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells." Eur J Immunol (September 9, 2011).  Full Text  Link to Item
    • Wong, NS, Fernando, NH, Bendell, JC, Morse, MA, Blobe, GC, Honeycutt, W, Pang, H, and Hurwitz, HI. "A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer." Clinical Colorectal Cancer 10, no. 3 (September 2011): 210-216.  Full Text
    • Hartman, ZC, Yang, X-Y, Glass, O, Lei, G, Osada, T, Dave, SS, Morse, MA, Clay, TM, and Lyerly, HK. "HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis." Cancer Research 71, no. 13 (July 2011): 4380-4391.  Full Text
    • Morse, MA, Chapman, R, Powderly, J, Blackwell, K, Keler, T, Green, J, Riggs, R, He, L-Z, Ramakrishna, V, Vitale, L, Zhao, B, Butler, SA, Hobeika, A, Osada, T, Davis, T, Clay, T, and Lyerly, HK. "Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 17, no. 14 (July 2011): 4844-4853.  Full Text
    • Hansen, NL, Chandiramani, DV, Morse, MA, Wei, D, Hedrick, NE, and Hansen, RA. "Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 17, no. 2 (June 2011): 125-130.  Full Text
    • Morse, MA, Bradley, DA, Keler, T, Laliberte, RJ, Green, JA, Davis, TA, and Inman, BA. "CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer." Expert Review of Vaccines 10, no. 6 (June 2011): 733-742. (Review)  Full Text
    • Osada, T, Chen, M, Yang, XY, Spasojevic, I, Vandeusen, JB, Hsu, D, Clary, BM, Clay, TM, Chen, W, Morse, MA, and Lyerly, HK. "Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations." Cancer Research 71, no. 12 (June 2011): 4172-4182.  Full Text
    • Morse, MA, Secord, AA, Blackwell, K, Hobeika, AC, Sinnathamby, G, Osada, T, Hafner, J, Philip, M, Clay, TM, Lyerly, HK, and Philip, R. "MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer." Clin Cancer Res 17, no. 10 (May 15, 2011): 3408-3419.  Full Text  Link to Item
    • Sanoff, HK, Bernard, S, Goldberg, RM, Morse, MA, Garcia, R, Woods, L, Moore, DT, and O'Neil, BH. "Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma." Gastrointestinal Cancer Research 4, no. 3 (May 1, 2011): 78-83.
    • Shetty, V, Sinnathamby, G, Nickens, Z, Shah, P, Hafner, J, Mariello, L, Kamal, S, Vlahović, G, Lyerly, HK, Morse, MA, and Philip, R. "MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response." Journal of Proteomics 74, no. 5 (May 2011): 728-743.  Full Text
    • Clay, TM, Osada, T, Hartman, ZC, Hobeika, A, Devi, G, Morse, MA, and Lyerly, HK. "Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines." Immunol Res 49, no. 1-3 (April 2011): 235-247.  Full Text  Link to Item
    • Sinnathamby, G, Zerfass, J, Hafner, J, Block, P, Nickens, Z, Hobeika, A, Secord, AA, Lyerly, HK, Morse, MA, and Philip, R. "ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers." Clin Exp Immunol 163, no. 3 (March 2011): 324-332.  Full Text  Link to Item
    • Bullock, KE, Petros, WP, Younis, I, Uronis, HE, Morse, MA, Blobe, GC, Zafar, SY, Gockerman, JP, Lager, JJ, Truax, R, Meadows, KL, Howard, LA, O'Neill, MM, Broadwater, G, Hurwitz, HI, and Bendell, JC. "A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)." Cancer Chemotherapy and Pharmacology 67, no. 2 (February 2011): 465-474.  Full Text
    • Castaneda, C, Meadows, KL, Truax, R, Morse, MA, Kaufmann, SH, Petros, WP, Zhu, Y, Statkevich, P, Cutler, DL, and Hurwitz, HI. "Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors." Cancer Chemother Pharmacol 67, no. 2 (February 2011): 455-463.  Full Text  Link to Item
    • Altomare, I, Bendell, JC, Bullock, KE, Uronis, HE, Morse, MA, Hsu, SD, Zafar, SY, Blobe, GC, Pang, H, Honeycutt, W, Sutton, L, and Hurwitz, HI. "A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer." The Oncologist 16, no. 8 (January 2011): 1131-1137.  Full Text
    • Hobeika, AC, Morse, MA, Osada, T, Peplinski, S, Lyerly, HK, and Clay, TM. "Depletion of human regulatory T cells." Methods Mol Biol 707 (2011): 219-231.  Full Text  Link to Item
    • Wong, NS, Fernando, NH, Nixon, AB, Cushman, S, Aklilu, M, Bendell, JC, Morse, MA, Blobe, GC, Ashton, J, Pang, H, and Hurwitz, HI. "A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer." Anticancer Research 31, no. 1 (January 2011): 255-261.
    • Hanks, BA, and Morse, MA. "Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response." Current Opinion in Investigational Drugs (London, England : 2000) 11, no. 12 (December 2010): 1342-1353. (Review)
    • Morse, MA, Hobeika, AC, Osada, T, Berglund, P, Hubby, B, Negri, S, Niedzwiecki, D, Devi, GR, Burnett, BK, Clay, TM, Smith, J, and Lyerly, HK. "An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer." The Journal of Clinical Investigation 120, no. 9 (September 2010): 3234-3241.  Full Text  Open Access Copy
    • Hsu, DS, Kim, MK, Balakumaran, BS, Acharya, CR, Anders, CK, Clay, T, Lyerly, HK, Drake, CG, Morse, MA, and Febbo, PG. "Immune signatures predict prognosis in localized cancer." Cancer Investigation 28, no. 7 (August 2010): 765-773.  Full Text
    • Morse, MA, Wei, J, Hartman, Z, Xia, W, Ren, X-R, Lei, G, Barry, WT, Osada, T, Hobeika, AC, Peplinski, S, Jiang, H, Devi, GR, Chen, W, Spector, N, Amalfitano, A, Lyerly, HK, and Clay, TM. "Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo." Int J Cancer 126, no. 12 (June 15, 2010): 2893-2903.  Full Text  Link to Item
    • Clarke, JM, Morse, MA, Lyerly, HK, Clay, T, and Osada, T. "Adenovirus vaccine immunotherapy targeting WT1-expressing tumors." Expert Opin Biol Ther 10, no. 6 (June 2010): 875-883. (Review)  Full Text  Link to Item
    • Osada, T, Hsu, D, Hammond, S, Hobeika, A, Devi, G, Clay, TM, Lyerly, HK, and Morse, MA. "Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody." Cancer Research 70, no. 8 Supplement (April 15, 2010): 5338-5338.  Full Text
    • Peters, KB, McLendon, R, Morse, MA, and Vredenburgh, JJ. "Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report. (Published online)" Case Rep Oncol 3, no. 1 (April 8, 2010): 93-97.  Full Text  Link to Item
    • Dugan, E, Truax, R, Meadows, KL, Nixon, AB, Petros, WP, Favaro, J, Fernando, NH, Morse, MA, Blobe, GC, and Hurwitz, HI. "A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors." Anticancer Res 30, no. 4 (April 2010): 1251-1256.  Link to Item
    • Hartman, ZC, Wei, J, Osada, T, Glass, O, Lei, G, Yang, X-Y, Peplinski, S, Kim, D-W, Xia, W, Spector, N, Marks, J, Barry, W, Hobeika, A, Devi, G, Amalfitano, A, Morse, MA, Lyerly, HK, and Clay, TM. "An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 16, no. 5 (March 2010): 1466-1477.  Full Text
    • Morse, MA, and Whelan, M. "A year of successful cancer vaccines points to a path forward." Curr Opin Mol Ther 12, no. 1 (February 2010): 11-13. (Review)  Link to Item
    • Merika, E, Saif, MW, Katz, A, Syrigos, C, and Morse, M. "Colon cancer vaccines: An update." In Vivo 24, no. 5 (2010): 607-628.
    • Osada, T, Hsu, D, Hammond, S, Hobeika, A, Devi, G, Clay, TM, Lyerly, HK, and Morse, MA. "Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody." British Journal of Cancer 102, no. 1 (January 2010): 124-133.  Full Text
    • Zafar, SY, Marcello, JE, Wheeler, JL, Rowe, KL, Morse, MA, Herndon, JE, and Abernethy, AP. "Treatment-related toxicity and supportive care in metastatic colorectal cancer." J Support Oncol 8, no. 1 (January 2010): 15-20.  Link to Item
    • Dugan, E, Truax, R, Meadows, KL, Blobe, GC, Morse, MA, Fernando, NH, Gockerman, JP, Petros, WP, and Hurwitz, HI. "Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors." Anticancer Res 29, no. 12 (December 2009): 5149-5153.  Link to Item
    • Sinnathamby, G, Lauer, P, Zerfass, J, Hanson, B, Karabudak, A, Krakover, J, Secord, AA, Clay, TM, Morse, MA, Dubensky, TW, Brockstedt, DG, Philip, R, and Giedlin, M. "Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines." J Immunother 32, no. 8 (October 2009): 856-869.  Full Text  Link to Item
    • Iversen, PL, Aird, KM, Wu, R, Morse, MM, and Devi, GR. "Cellular uptake of neutral phosphorodiamidate morpholino oligomers." Current pharmaceutical biotechnology 10, no. 6 (September 2009): 579-588. (Academic Article)
    • Osada, T, Yang, XY, Hartman, ZC, Glass, O, Hodges, BL, Niedzwiecki, D, Morse, MA, Lyerly, HK, Amalfitano, A, and Clay, TM. "Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity." Cancer Gene Ther 16, no. 9 (September 2009): 673-682.  Full Text  Link to Item
    • Zafar, SY, Marcello, JE, Wheeler, JL, Rowe, KL, Morse, MA, Herndon, JE, and Abernethy, AP. "Longitudinal patterns of chemotherapy use in metastatic colorectal cancer." Journal of Oncology Practice 5, no. 5 (September 2009): 228-233.  Full Text
    • Johnson, B, Osada, T, Clay, T, Lyerly, H, and Morse, M. "Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression." Curr Mol Med 9, no. 6 (August 2009): 702-707. (Review)  Link to Item
    • Ribas, A, Kirkwood, JM, Atkins, MB, Whiteside, TL, Gooding, W, Kovar, A, Gillies, SD, Kashala, O, and Morse, MA. "Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. (Published online)" J Transl Med 7 (July 29, 2009): 68-.  Full Text  Link to Item
    • Cohen, SJ, Punt, CJA, Iannotti, N, Saidman, BH, Sabbath, KD, Gabrail, NY, Picus, J, Morse, MA, Mitchell, E, Miller, MC, Doyle, GV, Tissing, H, Terstappen, LWMM, and Meropol, NJ. "Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 20, no. 7 (July 2009): 1223-1229.  Full Text
    • Reddy, SK, Zorzi, D, Lum, YW, Barbas, AS, Pawlik, TM, Ribero, D, Abdalla, EK, Choti, MA, Kemp, C, Vauthey, J-N, Morse, MA, White, RR, and Clary, BM. "Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis." Annals of Surgical Oncology 16, no. 7 (July 2009): 1809-1819.  Full Text
    • Bullock, KE, Hurwitz, HI, Uronis, HE, Morse, MA, Blobe, GC, Hsu, SD, Zafar, SY, Nixon, AB, Howard, LA, and Bendell, JC. "Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 4080-.
    • Osada, T, Woo, CY, McKinney, M, Yang, XY, Lei, G, Labreche, HG, Hartman, ZC, Niedzwiecki, D, Chao, N, Amalfitano, A, Morse, MA, Lyerly, HK, and Clay, TM. "Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 15, no. 8 (April 7, 2009): 2789-2796.  Full Text
    • Morse, MA, Hall, JR, and Plate, JMD. "Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer." Expert Opin Biol Ther 9, no. 3 (March 2009): 331-339. (Review)  Full Text  Link to Item
    • Morse, MA, and Whelan, M. "Turning lemons into lemonade: learning from negative studies in cancer immunotherapy." Curr Opin Mol Ther 11, no. 1 (February 2009): 10-12.  Link to Item
    • Nelson, JW, Ghafoori, AP, Willett, CG, Tyler, DS, Pappas, TN, Clary, BM, Hurwitz, HI, Bendell, JC, Morse, MA, Clough, RW, and Czito, BG. "Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma." International Journal of Radiation Oncology, Biology, Physics 73, no. 1 (January 2009): 148-153.  Full Text
    • Reddy, SK, Broadwater, G, Niedzwiecki, D, Barbas, AS, Hurwitz, HI, Bendell, JC, Morse, MA, and Clary, BM. "Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study." J Gastrointest Surg 13, no. 1 (January 2009): 74-84.  Full Text  Link to Item
    • Shah, U, O'Neil, B, Allen, J, Goldberg, RM, Bernard, S, Moore, D, Venook, AP, and Morse, MM. "A phase II study of long-acting octeotride in patients with advanced hepatocellular carcinoma and CLIP score of 3 or higher." Gastrointestinal Cancer Research 3, no. 2 (2009): 45-48.
    • Morse, MA. "Status of colon cancer vaccines. [An interview with Michael Morse by H&O]." Clin Adv Hematol Oncol 6, no. 11 (November 2008): 789-794. (Interview)  Link to Item
    • Morse, MA, Hobeika, AC, Osada, T, Serra, D, Niedzwiecki, D, Lyerly, HK, and Clay, TM. "Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines." Blood 112, no. 3 (August 2008): 610-618.  Full Text
    • Osada, T, Chong, G, Tansik, R, Hong, T, Spector, N, Kumar, R, Hurwitz, HI, Dev, I, Nixon, AB, Lyerly, HK, Clay, T, and Morse, MA. "The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients." Cancer Immunology, Immunotherapy : Cii 57, no. 8 (August 2008): 1115-1124.  Full Text
    • Cohen, SJ, Punt, CJA, Iannotti, N, Saidman, BH, Sabbath, KD, Gabrail, NY, Picus, J, Morse, M, Mitchell, E, Miller, MC, Doyle, GV, Tissing, H, Terstappen, LWMM, and Meropol, NJ. "Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 19 (July 2008): 3213-3221.  Full Text
    • Abernethy, AP, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Herndon, JE. "Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC)." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15087-.  Link to Item
    • Abernethy, AP, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and II, HJE. "Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Barve, M, Bender, J, Pappen, B, Ishioka, G, Morse, MA, Greco, FA, McCune, D, Steis, R, Khong, H, Nemunaitis, JJ, and Network, MCMRT. "Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Bendell, JC, Uronis, HE, Morse, MA, Blobe, G, Aklilu, M, Nixon, A, Niedzweicki, D, Honeycutt, W, Howard, L, and Hurwitz, H. "Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC)." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4063-.  Link to Item
    • Bendell, JC, Uronis, HE, Morse, MA, Blobe, G, Aklilu, M, Nixon, A, Niedzweicki, D, Honeycutt, W, Howard, L, and Hurwitz, H. "Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Hanks, BA, Suhocki, PV, DeLong, DM, Doan, PL, Liu, E, Tsai, AL, Burke, CT, Bernard, SA, O’Neil, BH, and Morse, MA. "The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4595-4595.  Full Text
    • Herndon, JE, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Abernethy, AP. "Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15082-.  Link to Item
    • II, HJE, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Abernethy, AP. "Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Morse, MA, Babich, JW, LaFrance, N, Kacena, KA, Gockerman, J, Moore, J, and Coleman, RE. "A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • O'Neil, BH, Bernard, SA, Goldberg, RM, Moore, DT, Garcia, R, Marroquin, C, Morse, MA, Woods, L, and Sanoff, HK. "Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 4604-.  Link to Item
    • O'Neil, BH, Bernard, SA, Goldberg, RM, Moore, DT, Garcia, R, Marroquin, C, Morse, MA, Woods, L, and Sanoff, HK. "Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Uronis, HE, Herndon, JE, Coan, A, Bronson, K, Wheeler, J, Lyerly, HK, Morse, MA, and Abernethy, AP. "E/Tablets to collect research-quality, patient-reported data." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528-.  Link to Item
    • Barve, M, Bender, J, Pappen, B, Ishioka, G, Morse, MA, Greco, FA, McCune, D, Steis, R, Khong, H, and Nemunaitis, JJ. "Induction of immune responses and clinical activity in a phase II trial of IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 8057-.
    • Clay, TM, Hobeika, A, Osada, T, Serra, D, Niedzwiecki, D, Lyerly, HK, and Morse, MA. "Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 3010-.
    • Hanks, BA, Suhocki, PV, DeLong, DM, Doan, PL, Liu, E, Tsai, AL, Burke, CT, Bernard, SA, O'Neil, BH, and Morse, MA. "The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 4595-null.
    • Morse, MA, Babich, JW, LaFrance, N, Kacena, KA, Gockerman, J, Moore, J, and Coleman, RE. "A phase I study of Iobenguane I 131 to evaluate MTD, efficacy and safety in patients with malignant pheochromocytoma/paraganglioma (Pheo)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 4605-.
    • Maecker, HT, Hassler, J, Payne, JK, Summers, A, Comatas, K, Ghanayem, M, Morse, MA, Clay, TM, Lyerly, HK, Bhatia, S, Ghanekar, SA, Maino, VC, Delarosa, C, and Disis, ML. "Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides." Bmc Immunology 9 (March 17, 2008): 9-null.  Full Text
    • Chung, CH, Mirakhur, B, Chan, E, Le, Q-T, Berlin, J, Morse, M, Murphy, BA, Satinover, SM, Hosen, J, Mauro, D, Slebos, RJ, Zhou, Q, Gold, D, Hatley, T, Hicklin, DJ, and Platts-Mills, TAE. "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose." The New England Journal of Medicine 358, no. 11 (March 2008): 1109-1117.  Full Text
    • Whelan, M, and Morse, MA. "When is an adjuvant not an adjuvant? Overview." Curr Opin Mol Ther 10, no. 1 (February 2008): 8-9.  Link to Item
    • Aird, KM, Ding, X, Baras, A, Wei, J, Morse, MA, Clay, T, Lyerly, HK, and Devi, GR. "Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression." Mol Cancer Ther 7, no. 1 (January 2008): 38-47.  Full Text  Link to Item
    • Barve, M, Bender, J, Senzer, N, Cunningham, C, Greco, FA, McCune, D, Steis, R, Khong, H, Richards, D, Stephenson, J, Ganesa, P, Nemunaitis, J, Ishioka, G, Pappen, B, Nemunaitis, M, Morse, M, Mills, B, Maples, PB, Sherman, J, and Nemunaitis, JJ. "Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer." Journal of Clinical Oncology 26, no. 27 (2008): 4418-4425.  Full Text
    • Hobeika, A, Osada, T, Serra, D, Peplinski, S, Hanson, K, Tanaka, Y, Niedzwiecki, D, Chao, N, Rizzieri, D, Lyerly, H, Clay, T, and Morse, M. "Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease." Cytotherapy 10, no. 3 (2008): 289-302.  Full Text  Link to Item
    • Khan, MU, Morse, M, and Coleman, RE. "Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors." Quarterly Journal of Nuclear Medicine and Molecular Imaging 52, no. 4 (2008): 441-454.
    • McKinney, M, and Morse, MA. "Advances in immunotherapy for colorectal malignancies." Current Colorectal Cancer Reports 4, no. 4 (2008): 177-183.  Full Text
    • Morse, M. "Comment regarding benefit in phase 1 oncology trials." Clinical Trials (London, England) 5, no. 6 (January 2008): 626-630.  Full Text
    • Morse, M. "Foreword." Expert Opinion on Biological Therapy 8, no. 1 (2008).
    • Morse, MA, and Willett, CG. "An odd but synergistic couple: Immunotherapy combined with radiotherapy." ONCOLOGY 22, no. 9 (2008): 1075-1080.
    • Reddy, SK, Morse, MA, Hurwitz, HI, Bendell, JC, Gan, TJ, Hill, SE, and Clary, BM. "Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases." J Am Coll Surg 206, no. 1 (January 2008): 96-106.  Full Text  Link to Item
    • Whelan, M, and Morse, MA. "When is an adjuvant not an adjuvant?." Current Opinion in Molecular Therapeutics 10, no. 1 (2008): 8-9.
    • Kelsey, CR, Nelson, JW, Willett, CG, Chino, JP, Clough, RW, Bendell, JC, Tyler, DS, Hurwitz, HI, Morse, MA, Clary, BM, Pappas, TN, and Czito, BG. "Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy." International Journal of Radiation Oncology, Biology, Physics 69, no. 5 (December 2007): 1436-1441.  Full Text
    • Patwardhan, M, Fisher, DA, Mantyh, CR, McCrory, DC, Morse, MA, Prosnitz, RG, Cline, K, and Samsa, GP. "Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature)." J Eval Clin Pract 13, no. 6 (December 2007): 831-845. (Review)  Full Text  Link to Item
    • Reddy, SK, Pawlik, TM, Zorzi, D, Gleisner, AL, Ribero, D, Assumpcao, L, Barbas, AS, Abdalla, EK, Choti, MA, Vauthey, J-N, Ludwig, KA, Mantyh, CR, Morse, MA, and Clary, BM. "Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis." Annals of Surgical Oncology 14, no. 12 (December 2007): 3481-3491.  Full Text
    • Kelsey, CR, Chino, JP, Willett, CG, Clough, RW, Hurwitz, HI, Morse, MA, Bendell, JC, D'Amico, TA, and Czito, BG. "Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer." Int J Radiat Oncol Biol Phys 69, no. 3 (November 1, 2007): 770-776.  Full Text  Link to Item
    • Clavien, PA, Baillie, J, Morse, MA, and Selzner, M. "Diseases of the Gallbladder and Bile Ducts: Diagnosis and Treatment: Second Edition." Diseases of the Gallbladder and Bile Ducts: Diagnosis and Treatment: Second Edition (October 25, 2007): 1-428.  Full Text
    • Morse, MA, and Pestalozzi, B. "Medical and Innovative Therapies for Biliary Malignancies." (October 25, 2007): 205-214. (Chapter)  Full Text
    • Morse, M, Langer, L, Starodub, A, Hobeika, A, Clay, T, and Lyerly, HK. "Current immunotherapeutic strategies in colon cancer." Surg Oncol Clin N Am 16, no. 4 (October 2007): 873-x. (Review)  Full Text  Link to Item
    • Saltz, LB, Lenz, H-J, Kindler, HL, Hochster, HS, Wadler, S, Hoff, PM, Kemeny, NE, Hollywood, EM, Gonen, M, Quinones, M, Morse, M, and Chen, HX. "Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 29 (October 2007): 4557-4561.  Full Text
    • Morse, MA, Hobeika, A, Osada, T, Niedzwiecki, D, Marcom, PK, Blackwell, KL, Anders, C, Devi, GR, Lyerly, HK, and Clay, TM. "Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. (Published online)" J Transl Med 5 (September 6, 2007): 42-.  Full Text  Link to Item
    • Langer, LF, Clay, TM, and Morse, MA. "Update on anti-CTLA-4 antibodies in clinical trials." Expert Opin Biol Ther 7, no. 8 (August 2007): 1245-1256. (Review)  Full Text  Link to Item
    • Murad, YM, Clay, TM, Lyerly, HK, and Morse, MA. "CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy." Expert Opin Biol Ther 7, no. 8 (August 2007): 1257-1266. (Review)  Full Text  Link to Item
    • Demetri, GD, Benjamin, RS, Blanke, CD, Blay, JY, Casali, P, Choi, H, Corless, CL, Debiec-Rychter, M, DeMatteo, RP, Ettinger, DS, Fisher, GA, Fletcher, CDM, Gronchi, A, Hohenberger, P, Hughes, M, Joensuu, H, Judson, I, Le Cesne, A, Maki, RG, Morse, M, Pappo, AS, Pisters, PWT, Raut, CP, Reichardt, P, Tyler, DS, Van Den Abbeele, AD, Von Mehren, M, Wayne, JD, and Zalcberg, J. "NCCN task force report: Management of patients with Gastrointestinal Stromal Tumor (GIST) - Update of the NCCN clinical practice guidelines." JNCCN Journal of the National Comprehensive Cancer Network 5, no. SUPPL. 2 (July 20, 2007). (Review)
    • Hu, Z, Yang, XY, Liu, Y, Sankin, GN, Pua, EC, Morse, MA, Lyerly, HK, Clay, TM, and Zhong, P. "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.(Published online)" J Transl Med 5 (July 11, 2007): 34-null.  Full Text  Link to Item
    • Demetri, GD, Benjamin, RS, Blanke, CD, Blay, J-Y, Casali, P, Choi, H, Corless, CL, Debiec-Rychter, M, DeMatteo, RP, Ettinger, DS, Fisher, GA, Fletcher, CDM, Gronchi, A, Hohenberger, P, Hughes, M, Joensuu, H, Judson, I, Le Cesne, A, Maki, RG, Morse, M, Pappo, AS, Pisters, PWT, Raut, CP, Reichardt, P, Tyler, DS, Van den Abbeele, AD, von Mehren, M, Wayne, JD, Zalcberg, J, and NCCN Task Force, . "NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines." J Natl Compr Canc Netw 5 Suppl 2 (July 2007): S1-29. (Review)  Link to Item
    • Czito, BG, Bendell, JC, Willett, CG, Morse, MA, Blobe, GC, Tyler, DS, Thomas, J, Ludwig, KA, Mantyh, CR, Ashton, J, Yu, D, and Hurwitz, HI. "Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results." Int J Radiat Oncol Biol Phys 68, no. 2 (June 1, 2007): 472-478.  Full Text  Link to Item
    • Johnson, BF, Clay, TM, Hobeika, AC, Lyerly, HK, and Morse, MA. "Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy." Expert Opin Biol Ther 7, no. 4 (April 2007): 449-460. (Review)  Full Text  Link to Item
    • Czito, BG, Kelsey, CR, Hurwitz, HI, Willett, CG, Morse, MA, Blobe, GC, Fernando, NH, D'Amico, TA, Harpole, DH, Honeycutt, W, Yu, D, and Bendell, JC. "A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma." Int J Radiat Oncol Biol Phys 67, no. 4 (March 15, 2007): 1002-1007.  Full Text  Link to Item
    • Reddy, SK, Barbas, AS, Marroquin, CE, Morse, MA, Kuo, PC, and Clary, BM. "Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis." Journal of the American College of Surgeons 204, no. 3 (March 2007): 372-382.  Full Text
    • Dalgleish, A, Emerich, D, Glassy, M, Kreitman, RJ, Mironov, V, Morse, M, and Santini, D. "Editorial Board Focus – February 2007." Expert Opinion on Biological Therapy 7, no. 2 (February 2007): 157-160.  Full Text
    • Hutchings, Y, Osada, T, Woo, CY, Clay, TM, Lyerly, HK, and Morse, MA. "Immunotherapeutic targeting of Wilms' tumor protein." Curr Opin Mol Ther 9, no. 1 (February 2007): 62-69. (Review)  Link to Item
    • Morse, MA, and Whelan, M. "Learning from each other: Applying observations from anti-tumor, anti-pathogen and anti-toxin immunotherapy." Current Opinion in Molecular Therapeutics 9, no. 1 (2007): 10-11.
    • Mosca, PJ, Lyerly, HK, Clay, TM, and Morse, MA. "Dendritic cell vaccines." Frontiers in Bioscience : a Journal and Virtual Library 12 (January 2007): 4050-4060. (Review)  Full Text
    • Osada, T, Clay, TM, Woo, CY, Morse, MA, and Lyerly, HK. "Natural killer cell activation and dendritic cell-based vaccines." Minerva Biotecnologica 19, no. 3 (2007): 91-104.
    • Prosnitz, RG, Patwardhan, MB, Samsa, GP, Mantyh, CR, Fisher, DA, McCrory, DC, Cline, KE, Gray, RN, and Morse, MA. "Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review." Cancer 107, no. 10 (November 15, 2006): 2352-2360. (Review)  Full Text  Link to Item
    • Woo, CY, Osada, T, Clay, TM, Lyerly, HK, and Morse, MA. "Recent clinical progress in virus-based therapies for cancer." Expert Opin Biol Ther 6, no. 11 (November 2006): 1123-1134. (Review)  Full Text  Link to Item
    • Morse, M, Wu, P, Choi, S, Kim, TH, Brown, AS, Losurdo, M, and Bruno, G. "Structural and optical characterization of GaN heteroepitaxial films on SiC substrates." Applied Surface Science 253, no. 1 (October 2006): 232-235.  Full Text
    • Osada, T, Clay, T, Hobeika, A, Lyerly, HK, and Morse, MA. "NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity." Cancer Immunol Immunother 55, no. 9 (September 2006): 1122-1131.  Full Text  Link to Item
    • Osada, T, Clay, TM, Woo, CY, Morse, MA, and Lyerly, HK. "Dendritic cell-based immunotherapy." International Reviews of Immunology 25, no. 5-6 (September 2006): 377-413. (Review)  Full Text
    • Toloza, EM, Morse, MA, and Lyerly, HK. "Gene therapy for lung cancer." J Cell Biochem 99, no. 1 (September 1, 2006): 1-22. (Review)  Full Text  Link to Item
    • Brown, AS, Kim, T-H, Choi, S, Wu, P, Morse, M, Losurdo, M, Giangregorio, MM, Bruno, G, and Moto, A. "Growth of InN on 6H-SiC by plasma assisted molecular beam epitaxy." physica status solidi (c) 3, no. 6 (June 2006): 1531-1535.  Full Text
    • Kelsey, CR, Czito, BG, Bendell, JC, Willett, CG, Morse, MA, D'Amico, TA, Honeycutt, W, Franklin, A, Yu, D, and Hurwitz, HI. "A phase I study of capecitabine (CAP), carboplatin (CARB), paclitaxel (TAX) and external beam radiation therapy (EBRT) for patients with esophageal carcinoma (EC)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24, no. 18_suppl (June 2006): 14044-.
    • Losurdo, M, Giangregorio, MM, Bruno, G, Kim, TH, Wu, P, Choi, S, Morse, M, Brown, A, Masia, F, Polimeni, A, and Capizzi, M. "Modification of InN properties by interactions with hydrogen and nitrogen." Materials Research Society Symposium Proceedings 892 (May 15, 2006): 155-160.
    • Patwardhan, MB, Samsa, GP, McCrory, DC, Fisher, DA, Mantyh, CR, Morse, MA, Prosnitz, RG, Cline, KE, and Gray, RN. "Cancer care quality measures: diagnosis and treatment of colorectal cancer." Evid Rep Technol Assess (Full Rep) , no. 138 (May 2006): 1-116. (Review)  Link to Item
    • Morse, MA. "Supportive care in the management of colon cancer." Support Cancer Ther 3, no. 3 (April 1, 2006): 158-170.  Full Text  Link to Item
    • Bunce, C, and Morse, MA. "Fulfilling the promise of immunotherapy." Curr Opin Mol Ther 8, no. 1 (February 2006): 9-10. (Review)  Link to Item
    • Czito, BG, Hong, TJ, Cohen, DP, Petros, WP, Tyler, DS, Pappas, TN, Yu, D, Lee, CG, Lockhart, AC, Morse, MA, Fernando, N, and Hurwitz, HI. "A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract." Cancer Invest 24, no. 1 (February 2006): 9-17.  Full Text  Link to Item
    • Czito, BG, Willett, CG, Bendell, JC, Morse, MA, Tyler, DS, Fernando, NH, Mantyh, CR, Blobe, GC, Honeycutt, W, Yu, D, Clary, BM, Pappas, TN, Ludwig, KA, and Hurwitz, HI. "Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24, no. 4 (February 2006): 656-662.  Full Text
    • Woo, CY, Clay, TM, Lyerly, HK, Morse, MA, and Osada, T. "Role of natural killer cell function in dendritic cell-based vaccines." Expert Rev Vaccines 5, no. 1 (February 2006): 55-65. (Review)  Full Text  Link to Item
    • Bunce, C, and Morse, MA. "Editorial overview: Fulfilling the promise of immunotherapy." Current Opinion in Molecular Therapeutics 8, no. 1 (2006): 9-10.
    • Hu, Z, Yang, XY, Liu, Y, Morse, MA, Lyerly, HK, Clay, TM, and Zhong, P. "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model." AIP Conference Proceedings 829 (2006): 241-245.  Full Text
    • Lou, E, Marshall, J, Aklilu, M, Cole, D, Chang, D, and Morse, M. "A phase II study of active immunotherapy with PANVAC^TM or autologous, cultured dendritic cells infected with PANVAC^TM after complete resection of hepatic metastases of colorectal carcinoma." Clinical Colorectal Cancer 5, no. 5 (2006): 368-371.  Full Text
    • Osada, T, and Morse, MA. "Immunization with fowlpox vector-modified dendritic cell in patients with carcinoembryonic antigen-expressing cancer: Phase I clinical study." Biotherapy 20, no. 6 (2006): 541-548.
    • Chong, G, and Morse, MA. "Combining cancer vaccines with chemotherapy." Expert Opin Pharmacother 6, no. 16 (December 2005): 2813-2820. (Review)  Full Text  Link to Item
    • Chong, GT, Kim, RJ, Ambati, SR, Wong, TZ, Dibernardo, LR, Merkle, EM, Ryan, T, and Morse, MA. "Diagnosis of a solitary cardiac metastasis from ocular melanoma." J Thorac Cardiovasc Surg 130, no. 6 (December 2005): 1727-1728.  Full Text  Link to Item
    • Morse, MA. "Virus-based therapies for colon cancer." Expert Opin Biol Ther 5, no. 12 (December 2005): 1627-1633. (Review)  Full Text  Link to Item
    • Morse, MA. "Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer." IDrugs 8, no. 12 (December 2005): 974-977.  Link to Item
    • Morse, MA. "Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb." Current Opinion in Molecular Therapeutics 7, no. 6 (December 2005): 588-597.
    • Smith, AD, Morse, MA, and Kuo, PC. "Case 23-2005: a man with a mass in the liver." N Engl J Med 353, no. 20 (November 17, 2005): 2195-2197. (Letter)  Link to Item
    • Smith, AD, Morse, MA, and Kuo, PC. "Case 23-2005: A man with a mass in the liver." NEW ENGLAND JOURNAL OF MEDICINE 353, no. 20 (November 17, 2005): 2196-2196.  Link to Item
    • Brown, AS, Losurdo, M, Kim, TH, Giangregorio, MM, Choi, S, Morse, M, Wu, P, Capezzuto, P, and Bruno, G. "The impact of SiC substrate treatment on the heteroepitaxial growth of GaN by plasma assisted MBE." Crystal Research and Technology 40, no. 10-11 (November 2005): 997-1002.  Full Text
    • Hu, Z, Yang, XY, Liu, Y, Morse, MA, Lyerly, HK, Clay, TM, and Zhong, P. "Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs." Biochem Biophys Res Commun 335, no. 1 (September 16, 2005): 124-131.  Full Text  Link to Item
    • Osada, T, Morse, MA, Lyerly, HK, and Clay, TM. "Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs." Int Immunol 17, no. 9 (September 2005): 1143-1155.  Full Text  Link to Item
    • Chui, SY, Clay, TM, Lyerly, HK, and Morse, MA. "The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori." Cancer Epidemiol Biomarkers Prev 14, no. 8 (August 2005): 1883-1889. (Review)  Full Text  Link to Item
    • Morse, MA. "Adjuvant therapy of colon cancer: current status and future developments." Clin Colon Rectal Surg 18, no. 3 (August 2005): 224-231.  Full Text  Link to Item
    • Maecker, HT, Moon, J, Bhatia, S, Ghanekar, SA, Maino, VC, Payne, JK, Kuus-Reichel, K, Chang, JC, Summers, A, Clay, TM, Morse, MA, Lyerly, HK, DeLaRosa, C, Ankerst, DP, and Disis, ML. "Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT." Bmc Immunology 6 (July 18, 2005): 17-null.  Full Text
    • Czito, BG, Hurwitz, HI, Clough, RW, Tyler, DS, Morse, MA, Clary, BM, Pappas, TN, Fernando, NH, and Willett, CG. "Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience." International Journal of Radiation Oncology, Biology, Physics 62, no. 4 (July 2005): 1030-1034.  Full Text
    • Cohn, A, Morse, MA, O'Neil, B, Bellgrau, D, Duke, RC, Franzusoff, AJ, Munson, S, Ferraro, J, and Rodell, TC. "Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23, no. 16_suppl (June 2005): 2571-.
    • Richards, JM, Bedikian, A, Gonzalez, R, Atkins, MB, Whitman, E, Lutzky, J, Morse, MA, Amatruda, T, Galanis, E, and Thompson, J. "High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23, no. 16_suppl (June 2005): 7543-.
    • Mis, L, Fernando, NH, Hurwitz, HI, and Morse, MA. "Successful desensitization to oxaliplatin." The Annals of Pharmacotherapy 39, no. 5 (May 2005): 966-969.  Full Text
    • Morse, MA, Clay, TM, Hobeika, AC, Osada, T, Khan, S, Chui, S, Niedzwiecki, D, Panicali, D, Schlom, J, and Lyerly, HK. "Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules." Clin Cancer Res 11, no. 8 (April 15, 2005): 3017-3024.  Full Text  Link to Item
    • White, RR, Xie, HB, Gottfried, MR, Czito, BG, Hurwitz, HI, Morse, MA, Blobe, GC, Paulson, EK, Baillie, J, Branch, MS, Jowell, PS, Clary, BM, Pappas, TN, and Tyler, DS. "Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer." Annals of Surgical Oncology 12, no. 3 (March 3, 2005): 214-221.  Full Text
    • Morse, MA, Garst, J, Osada, T, Khan, S, Hobeika, A, Clay, TM, Valente, N, Shreeniwas, R, Sutton, MA, Delcayre, A, Hsu, D-H, Le Pecq, J-B, and Lyerly, HK. "A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer." Journal of Translational Medicine 3, no. 1 (February 21, 2005): 9-null.  Full Text
    • Morse, MA, Chui, S, Hobeika, A, Lyerly, HK, and Clay, T. "Recent developments in therapeutic cancer vaccines." Nat Clin Pract Oncol 2, no. 2 (February 2005): 108-113. (Review)  Full Text  Link to Item
    • Bunce, C, and Morse, MA. "Editorial overview: What is a vaccine?." Current Opinion in Molecular Therapeutics 7, no. 1 (2005): 9-10.
    • Hawkins, MA, Dawson, LA, Smith, AD, Morse, MA, Kuo, PC, Gans, H, Tanabe, KK, Chung, RT, and Blaszkowsky, LS. "Case 23-2005: A man with a mass in the liver [5] (multiple letters)." New England Journal of Medicine 353, no. 20 (2005): 2195-2197.  Full Text
    • Hobeika, AC, Morse, MA, Osada, T, Ghanayem, M, Niedzwiecki, D, Barrier, R, Lyerly, HK, and Clay, TM. "Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis." Journal of Immunotherapy (Hagerstown, Md. : 1997) 28, no. 1 (January 2005): 63-72.  Full Text
    • Kim, T-H, Choi, S, Morse, M, Wu, P, Yi, C, Brown, A, Losurdo, M, Giangregorio, MM, and Bruno, G. "Impact of unintentional and intentional nitridation of the 6H-SiC(0001)[sub Si] substrate on GaN epitaxy." Journal of Vacuum Science & Technology B: Microelectronics and Nanometer Structures 23, no. 3 (2005): 1181-1181.  Full Text
    • Morse, M. "Technology evaluation: Rexin-G, Epeius Biotechnologies." Current Opinion in Molecular Therapeutics 7, no. 2 (2005): 164-169.
    • Morse, MA. "Perspectives in Colorectal Cancer - Sixth Annual Conference. Metastatic colorectal cancer. 23-24 September 2005, Chicago, IL, USA." IDrugs 8, no. 12 (2005): 974-977.
    • Mosca, PJ, Clay, TM, Morse, MA, and Lyerly, HK. "Immune monitoring." Cancer Treat Res 123 (2005): 369-388. (Review)  Link to Item
    • Chui, SY, Morse, MA, Doldo, T, Osada, T, Clay, TM, Lyerly, HK, Khan, S, Gattis, A, and Hobeika, AC. "Regulatory and effector T cell subsets and dendritic cells in breast cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 9697-.
    • Ishioka, GY, Disis, ML, Morse, MA, Cunningham, CC, Lenz, HJ, Figlin, RA, Chesnut, RW, and Fikes, J. "A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 2525-.
    • Richards, J, Bedikian, AY, Gonzalez, R, Atkins, MB, Whitman, ED, Lutzky, J, Morse, MA, Amatruda, T, and Galanis, E. "A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 7509-.
    • Gerke, H, White, R, Byrne, MF, Stiffier, H, Mitchell, RM, Hurwitz, HI, Morse, MA, Branch, MS, Jowell, PS, Czito, B, Clary, B, Pappas, TN, Tyler, DS, and Baillie, J. "Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage." Dig Liver Dis 36, no. 6 (June 2004): 412-418.  Link to Item
    • Czito, BG, Hong, TJ, Cohen, DP, Tyler, DS, Lee, CG, Anscher, MS, Ludwig, KA, Seigler, HF, Mantyh, C, Morse, MA, Lockhart, AC, Petros, WP, Honeycutt, W, Spector, NL, Ertel, PJ, Mangum, SG, and Hurwitz, HI. "A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon." Int J Radiat Oncol Biol Phys 58, no. 3 (March 1, 2004): 779-785.  Full Text  Link to Item
    • Chui, S, Clay, TM, Mosca, PJ, Hobeika, AC, Osada, T, Galibert, L, Caron, D, Lyerly, HK, and Morse, MA. "Flt3-ligand as a vaccine adjuvant: Results in a study of Flt3-ligand plus tetanus toxoid immunization." Journal of Applied Research 4, no. 4 (2004): 536-549.
    • Morse, MA, Clay, TM, Hobeika, AC, Chui, S, Mosca, PJ, Caron, D, and Lyerly, HK. "Active immunotherapy with Flt3-ligand mobilized peripheral blood dendritic cells loaded with carcinoembryonic antigen peptide in patients with metastatic malignancies." Journal of Applied Research 4, no. 4 (2004): 554-569.
    • Morse, MA, Lyerly, HK, Clay, TM, Abdel-Wahab, O, Chui, SY, Garst, J, Gollob, J, Grossi, PM, Kalady, M, Mosca, PJ, Onaitis, M, Sampson, JH, Seigler, HF, Toloza, EM, Tyler, D, Vieweg, J, and Yang, Y. "Immunotherapy of surgical malignancies." Curr Probl Surg 41, no. 1 (January 2004): 15-132. (Review)  Full Text  Link to Item
    • Morse, MA, Lyerly, HK, Clay, TM, Abdel-Wahab, O, Chui, SY, Garst, J, Gollob, J, Grossi, PM, Kalady, M, Mosca, PJ, Onaitis, M, Sampson, JH, Seigler, HF, Toloza, EM, Tyler, D, Vieweg, J, and Yang, Y. "How does the immune system attack cancer?." Current Problems in Surgery 41, no. 1 (2004): 15-132.  Full Text
    • Micames, C, Jowell, PS, White, R, Paulson, E, Nelson, R, Morse, M, Hurwitz, H, Pappas, T, Tyler, D, and McGrath, K. "Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA." Gastrointestinal Endoscopy 58, no. 5 (November 2003): 690-695.  Full Text
    • Morse, MA, Clay, T, Colling, K, and Lyerly, HK. "Preparation of peptide-loaded dendritic cells for cancer immunotherapy." Mol Biotechnol 25, no. 1 (September 2003): 95-99.  Full Text  Link to Item
    • Fecci, PE, Mitchell, DA, Archer, GE, Morse, MA, Lyerly, HK, Bigner, DD, and Sampson, JH. "The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors." J Neurooncol 64, no. 1-2 (August 2003): 161-176. (Review)  Link to Item
    • Califf, RM, Morse, MA, Wittes, J, Goodman, SN, Nelson, DK, DeMets, DL, Iafrate, RP, and Sugarman, J. "Toward protecting the safety of participants in clinical trials." Controlled Clinical Trials 24, no. 3 (June 2003): 256-271.  Full Text
    • Morse, MA, Nair, SK, Mosca, PJ, Hobeika, AC, Clay, TM, Deng, Y, Boczkowski, D, Proia, A, Neidzwiecki, D, Clavien, P-A, Hurwitz, HI, Schlom, J, Gilboa, E, and Lyerly, HK. "Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA." Cancer Invest 21, no. 3 (June 2003): 341-349.  Link to Item
    • Onaitis, M, Morse, M, Hurwitz, H, Cotton, P, Tyler, D, Clavien, P, and Clary, B. "Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases." Ann Surg 237, no. 6 (June 2003): 782-788.  Full Text  Link to Item
    • Heneghan, MA, Tuttle-Newhall, JE, Suhocki, PV, Muir, AJ, Morse, M, Bornstein, JD, Sylvestre, PB, Collins, B, Kuo, PC, and Rockey, DC. "De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 3, no. 5 (May 2003): 634-638.  Full Text
    • Mosca, PJ, Clay, TM, Kim Lyerly, H, and Morse, MA. "Current status of dendritic cell immunotherapy of malignancies." Int Rev Immunol 22, no. 3-4 (May 2003): 255-281. (Review)  Link to Item
    • Bunce, CJ, and Morse, MA. "A need for effective adjuvants." Curr Opin Mol Ther 5, no. 1 (February 2003): 8-9.  Link to Item
    • Bunce, CJ, and Morse, MA. "Editorial overview - A need for effective adjuvants." CURRENT OPINION IN MOLECULAR THERAPEUTICS 5, no. 1 (February 2003): 8-9.  Link to Item
    • Morse, MA, Clay, TM, Colling, K, Hobeika, A, Grabstein, K, Cheever, MA, and Lyerly, HK. "HER2 dendritic cell vaccines." Clin Breast Cancer 3 Suppl 4 (February 2003): S164-S172.  Link to Item
    • Mosca, PJ, Lyerly, HK, Ching, CD, Hobeika, AC, Clay, TM, and Morse, MA. "Proteomics for monitoring immune responses to cancer vaccines." Curr Opin Mol Ther 5, no. 1 (February 2003): 39-43. (Review)  Link to Item
    • Fecci, PE, Mitchell, DA, Archer, GE, Morse, MA, Lyerly, HK, Bigner, DD, and Sampson, JH. "The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors." JOURNAL OF NEURO-ONCOLOGY 64, no. 1 (2003): 161-176.  Full Text  Link to Item
    • Morse, MA, Chui, S, Clay, TM, and Lyerly, HK. "Recent areas of development for dendritic cell vaccines." Cancer Chemother Biol Response Modif 21 (2003): 339-350. (Review)  Link to Item
    • Morse, MA, Clay, TM, Mosca, P, and Lyerly, HK. "Immunoregulatory T cells in cancer immunotherapy." Expert Opin Biol Ther 2, no. 8 (December 2002): 827-834. (Review)  Full Text  Link to Item
    • Morse, MA. "38th Annual Meeting of the American Society of Clinical Oncology. 18-21 May 2002, Orlando, Florida, USA." Expert Opin Emerg Drugs 7, no. 2 (October 2002): 335-338.  Full Text  Link to Item
    • Mosca, PJ, Hobeika, AC, Colling, K, Clay, TM, Thomas, EK, Caron, D, Lyerly, HK, and Morse, MA. "Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand." Journal of Leukocyte Biology 72, no. 3 (September 2002): 546-553.
    • Morse, MA, Rizzieri, D, Stenzel, TT, Hobeika, AC, Vredenburgh, JJ, Chao, NJ, Clay, TM, Mosca, PJ, and Lyerly, HK. "Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants." J Hematother Stem Cell Res 11, no. 4 (August 2002): 659-668.  Full Text  Link to Item
    • Morse, MA, and Lyerly, HK. "DNA and RNA modified dendritic cell vaccines." World Journal of Surgery 26, no. 7 (July 2002): 819-825. (Review)  Full Text
    • Clay, TM, Morse, M, and Lyerly, HK. "Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes." Expert Opin Biol Ther 2, no. 4 (April 2002): 353-360. (Review)  Full Text  Link to Item
    • Gasparetto, C, Gasparetto, M, Morse, M, Rooney, B, Vredenburgh, JJ, Long, GD, Rizzieri, DA, Loftis, J, Chao, NJ, and Smith, C. "Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF." Cytokine 18, no. 1 (April 2002): 8-19.  Full Text
    • Nair, SK, Morse, M, Boczkowski, D, Cumming, RI, Vasovic, L, Gilboa, E, and Lyerly, HK. "Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells." Ann Surg 235, no. 4 (April 2002): 540-549.  Link to Item
    • Morse, MA, Clay, TM, and Lyerly, HK. "Current status of adoptive immunotherapy of malignancies." Expert Opin Biol Ther 2, no. 3 (March 2002): 237-247. (Review)  Full Text  Link to Item
    • Bunce, CJ, and Morse, MA. "Priming, boosting, measuring." Curr Opin Mol Ther 4, no. 1 (February 2002): 13-14.  Link to Item
    • Bunce, CJ, and Morse, MA. "Editorial overview: Priming, boosting, measuring." Current Opinion in Molecular Therapeutics 4, no. 1 (2002): 13-14.
    • Chui, SY, and Morse, MA. "Vaccines and gene therapy for colorectal cancer." Seminars in Colon and Rectal Surgery 13, no. 4 (2002): 277-292.  Full Text
    • Clavien, P-A, Kang, KJ, Selzner, N, Morse, MA, and Suhocki, PV. "Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis." J Gastrointest Surg 6, no. 1 (January 2002): 95-101.  Link to Item
    • Clavien, P-A, Selzner, N, Morse, M, Selzner, M, and Paulson, E. "Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy." Surgery 131, no. 4 (2002): 433-442.  Full Text
    • Morse, MA, Clay, TM, and Lyerly, HK. "CEA loaded dendritic cell vaccines." Cancer Chemother Biol Response Modif 20 (2002): 385-390. (Review)  Link to Item
    • Morse, MA, Mosca, PJ, Clay, TM, and Lyerly, HK. "Dendritic cell maturation in active immunotherapy strategies." Expert Opin Biol Ther 2, no. 1 (January 2002): 35-43. (Review)  Full Text  Link to Item
    • Morse, MA, Mosca, PJ, Clay, TM, and Lyerly, HK. "Dendritic cell-based vaccines in cancer: Clinical experience to date." American Journal of Cancer 1, no. 5 (2002): 313-322.  Full Text
    • Morse, MA, Nair, SK, Boczkowski, D, Tyler, D, Hurwitz, HI, Proia, A, Clay, TM, Schlom, J, Gilboa, E, and Lyerly, HK. "The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer." Int J Gastrointest Cancer 32, no. 1 (2002): 1-6.  Full Text  Link to Item
    • Morse, MA. "Technology evaluation: ISIS-2503, Isis Pharmaceuticals." Curr Opin Mol Ther 3, no. 6 (December 2001): 589-594.  Link to Item
    • Onaitis, MW, Noone, RB, Fields, R, Hurwitz, H, Morse, M, Jowell, P, McGrath, K, Lee, C, Anscher, MS, Clary, B, Mantyh, C, Pappas, TN, Ludwig, K, Seigler, HF, and Tyler, DS. "Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival." Ann Surg Oncol 8, no. 10 (December 2001): 801-806.  Link to Item
    • White, RR, Hurwitz, HI, Morse, MA, Lee, C, Anscher, MS, Paulson, EK, Gottfried, MR, Baillie, J, Branch, MS, Jowell, PS, McGrath, KM, Clary, BM, Pappas, TN, and Tyler, DS. "Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas." Annals of Surgical Oncology 8, no. 10 (December 2001): 758-765.  Full Text
    • White, RR, Paulson, EK, Freed, KS, Keogan, MT, Hurwitz, HI, Lee, C, Morse, MA, Gottfried, MR, Baillie, J, Branch, MS, Jowell, PS, McGrath, KM, Clary, BM, Pappas, TN, and Tyler, DS. "Staging of pancreatic cancer before and after neoadjuvant chemoradiation." Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract 5, no. 6 (November 2001): 626-633.  Full Text
    • Morse, MA. "The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe?." Gastroenterology 121, no. 4 (October 2001): 1010-1013.  Link to Item
    • Morse, MA. "Technology evaluation: CEA-TRICOM, Therion Biologics Corp." Curr Opin Mol Ther 3, no. 4 (August 2001): 407-412.  Link to Item
    • Morse, MA. "American Society of Clinical Oncology - 37th Annual Meeting. Novel antitumor agents. 12-15 May 2001, San Francisco, CA, USA." IDrugs 4, no. 8 (August 2001): 853-856.  Link to Item
    • Morse, MA. "American Society of Clinical Oncology - 37th Annual Meeting. Small molecule tyrosine kinase inhibitors. 12-15 May 2001, San Francisco, CA, USA." IDrugs 4, no. 8 (August 2001): 857-859.  Link to Item
    • Tokunaga, K, Greenberg, ML, Morse, MA, Cumming, RI, Lyerly, HK, and Cullen, BR. "Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates." Journal of Virology 75, no. 15 (August 2001): 6776-6785.  Full Text
    • Gupta, A, Nines, R, Rodrigo, KA, Aziz, RA, Carlton, PS, Gray, DL, Steele, VE, Morse, MA, and Stoner, GD. "Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat." J Natl Cancer Inst 93, no. 13 (July 4, 2001): 990-998.  Link to Item
    • Burman, WJ, and Schooley, RT. "The role of local institutional review boards in protecting human research subjects." Jama 285, no. 21 (June 2001): 2713-null. (Letter)  Full Text
    • Onaitis, MW, Noone, RB, Hartwig, M, Hurwitz, H, Morse, M, Jowell, P, McGrath, K, Lee, C, Anscher, MS, Clary, B, Mantyh, C, Pappas, TN, Ludwig, K, Seigler, HF, and Tyler, DS. "Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience." Annals of Surgery 233, no. 6 (June 2001): 778-785.  Full Text
    • Clay, TM, Hobeika, AC, Mosca, PJ, Lyerly, HK, and Morse, MA. "Assays for monitoring cellular immune responses to active immunotherapy of cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 7, no. 5 (May 2001): 1127-1135. (Review)
    • Mallery, SR, Shenderova, A, Pei, P, Begum, S, Ciminieri, JR, Wilson, RF, Casto, BC, Schuller, DE, and Morse, MA. "Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model." Anticancer Res 21, no. 3B (May 2001): 1713-1722.  Link to Item
    • Morse, MA, Califf, RM, and Sugarman, J. "Monitoring and ensuring safety during clinical research." Jama 285, no. 9 (March 2001): 1201-1205.  Full Text
    • Mosca, PJ, Hobeika, AC, Clay, TM, Morse, MA, and Lyerly, HK. "Direct detection of cellular immune responses to cancer vaccines." Surgery 129, no. 3 (March 2001): 248-254. (Review)  Full Text
    • Morse, MA, Clay, TM, Hobeika, AC, Mosca, PJ, and Lyerly, HK. "Monitoring cellular immune responses to cancer immunotherapy." Curr Opin Mol Ther 3, no. 1 (February 2001): 45-52. (Review)  Link to Item
    • Morse, MA, and Bunce, C. "Editorial overview - A cornucopia of strategies for the immunotherapy of cancer." CURRENT OPINION IN MOLECULAR THERAPEUTICS 3, no. 1 (February 2001): 13-14.  Link to Item
    • Morse, MA. "Technology evaluation: BLP-25, Biomira Inc." Curr Opin Mol Ther 3, no. 1 (February 2001): 102-105. (Review)  Link to Item
    • Morse, MA. "Technology evaluation: VEGF165 gene therapy, Valentis Inc." Curr Opin Mol Ther 3, no. 1 (February 2001): 97-101. (Review)  Link to Item
    • Selzner, M, Bielawska, A, Morse, MA, Rüdiger, HA, Sindram, D, Hannun, YA, and Clavien, PA. "Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer." Cancer Research 61, no. 3 (February 2001): 1233-1240.
    • Hobeika, AC, Clay, TM, Mosca, PJ, Lyerly, HK, and Morse, MA. "Quantitating therapeutically relevant T-cell responses to cancer vaccines." Critical Reviews in Immunology 21, no. 1-3 (January 2001): 287-297. (Review)
    • Hudson, TS, Carlton, PS, Gupta, A, Stoner, GD, and Morse, MA. "Investigation of the enhancement of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis by 6-phenylhexyl isothiocyanate." Cancer Letters 162, no. 1 (January 2001): 19-26.  Full Text
    • Mallery, SR, Shenderova, A, Pei, P, Begum, S, Ciminieri, JR, Wilson, RF, Casto, BC, Schuller, DE, and Morse, MA. "Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model." Anticancer Research 21, no. 3 B (2001): 1713-1722.
    • Morse, MA, and Bunce, C. "A cornucopia of strategies for the immunotherapy of cancer." Current Opinion in Molecular Therapeutics 3, no. 1 (2001): 13-14.
    • Morse, MA, Nair, S, Fernandez-Casal, M, Deng, Y, St Peter, M, Williams, R, Hobeika, A, Mosca, P, Clay, T, Cumming, RI, Fisher, E, Clavien, P, Proia, AD, Niedzwiecki, D, Caron, D, and Lyerly, HK. "Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer." J Clin Oncol 18, no. 23 (December 1, 2000): 3883-3893.  Full Text  Link to Item
    • Mosca, PJ, Hobeika, AC, Clay, TM, Nair, SK, Thomas, EK, Morse, MA, and Lyerly, HK. "A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment." Blood 96, no. 10 (November 2000): 3499-3504.
    • Lyerly, HK, Clay, T, and Morse, MA. "Optimizing dendritic cell function by genetic modification." J Natl Cancer Inst 92, no. 15 (August 2, 2000): 1198-1199.  Link to Item
    • Morse, MA. "Technology evaluation: gene therapy (IL-2), Valentis Inc." Curr Opin Mol Ther 2, no. 4 (August 2000): 448-452. (Review)  Link to Item
    • Morse, MA. "Technology evaluation: Theratope, Biomira Inc." Curr Opin Mol Ther 2, no. 4 (August 2000): 453-458. (Review)  Link to Item
    • Morse, MA. "American Society of Clinical Oncology - 36th Annual Meeting." IDrugs 3, no. 8 (August 2000): 846-850.  Link to Item
    • Morse, MA, Bossen, E, D'Amico, TA, Williamson, W, and Johnson, R. "Myxoid liposarcoma of the supraclavicular fossa." Chest 117, no. 5 (May 2000): 1518-1520.  Link to Item
    • Selzner, M, Morse, MA, Vredenburgh, JJ, Meyers, WC, and Clavien, PA. "Liver metastases from breast cancer: long-term survival after curative resection." Surgery 127, no. 4 (April 2000): 383-389.  Full Text
    • Morse, MA. "Stem cell therapy (Aastrom Biosciences Inc)." IDrugs 3, no. 3 (March 2000): 346-353.  Link to Item
    • Morse, MA, and Lyerly, HK. "Clinical applications of dendritic cell vaccines." Curr Opin Mol Ther 2, no. 1 (February 2000): 20-28. (Review)  Link to Item
    • Mosca, PJ, Morse, MA, D'Amico, TA, Crawford, J, and Lyerly, HK. "Gene therapy for lung cancer." Clin Lung Cancer 1, no. 3 (February 2000): 218-226.  Link to Item
    • Bunce, C, and Morse, MA. "On the road to effective vaccine development." Current Opinion in Molecular Therapeutics 2, no. 1 (2000): 18-19.
    • Morse, MA, and Lyerly, HK. "Dendritic cell-based immunization for cancer therapy." Adv Exp Med Biol 465 (2000): 335-346. (Review)  Link to Item
    • Morse, MA. "Theratope Biomira Inc." Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs 2, no. 4 (2000): 405-413.
    • Morse, MA, Vredenburgh, JJ, and Lyerly, HK. "A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy." Journal of Hematotherapy & Stem Cell Research 8, no. 6 (December 1999): 577-584.  Full Text
    • Morse, MA. "Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc." Curr Opin Mol Ther 1, no. 6 (December 1999): 745-752. (Review)  Link to Item
    • Morse, MA, Lyerly, HK, and Li, Y. "The role of IL-13 in the generation of dendritic cells in vitro." Journal of Immunotherapy (Hagerstown, Md. : 1997) 22, no. 6 (November 1999): 506-513.
    • Clavien, PA, Selzner, M, and Morse, MA. "Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor." Ann Surg 230, no. 4 (October 1999): 607-610. (Letter)  Link to Item
    • Clavien, PA, Selzner, M, and Morse, MA. "Untitled." ANNALS OF SURGERY 230, no. 4 (October 1999): 607-608.  Full Text  Link to Item
    • Selzner, M, Morse, MA, Sindram, D, Bielawska, A, Hannun, YA, and Clavien, PA. "Ceramide analogue B13 induces apoptosis and completely inhibits growth of liver metastases from colon cancer in vivo a new strategy for the treatment of metastatic liver disease." HEPATOLOGY 30, no. 4 (October 1999): 161A-161A.  Link to Item
    • Lyerly, HK, and Morse, MA. "Carcinoembryonic antigen peptide-pulsed dendritic cells in patients with metastatic cancer." Clin Lung Cancer 1, no. 1 (August 1999): 70-72.  Link to Item
    • Nair, SK, Hull, S, Coleman, D, Gilboa, E, Lyerly, HK, and Morse, MA. "Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA." International Journal of Cancer 82, no. 1 (July 1999): 121-124.  Full Text
    • Morse, MA, Deng, Y, Coleman, D, Hull, S, Kitrell-Fisher, E, Nair, S, Schlom, J, Ryback, ME, and Lyerly, HK. "A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 5, no. 6 (June 1999): 1331-1338.
    • Morse, MA, and Lyerly, HK. "Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials." Ann Surg Oncol 6, no. 2 (March 1999): 218-223. (Review)  Link to Item
    • Clavien, P-A, Selzner, M, Morse, MA, Lorenz, M, and Muller, H-H. "Letter to the editor [1] (multiple letters)." Annals of Surgery 230, no. 4 (1999): 607-610.
    • Morse, MA, Coleman, RE, Akabani, G, Niehaus, N, Coleman, D, and Lyerly, HK. "Migration of human dendritic cells after injection in patients with metastatic malignancies." Cancer Research 59, no. 1 (January 1999): 56-58.
    • Morse, MA, and Lyerly, HK. "Dendritic cell-based approaches to cancer immunotherapy." Expert Opin Investig Drugs 7, no. 10 (October 1998): 1617-1627.  Full Text  Link to Item
    • Morse, MA, Lyerly, HK, Gilboa, E, Thomas, E, and Nair, SK. "Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells." Cancer Res 58, no. 14 (July 15, 1998): 2965-2968.  Link to Item
    • Morse, MA. "Inhibition of NNK-induced lung tumorigenesis by modulators of NNK activation." Exp Lung Res 24, no. 4 (July 1998): 595-604.  Link to Item
    • Morse, MA, and Lu, J. "High-performance liquid chromatographic method for measurement of cytochrome P450-mediated metabolism of 7-ethoxy-4-trifluoromethylcoumarin." J Chromatogr B Biomed Sci Appl 708, no. 1-2 (April 24, 1998): 290-293.  Link to Item
    • Miralles, GD, Smith, CA, Whichard, LP, Morse, MA, Haynes, BF, and Patel, DD. "CD34+CD38-lin- cord blood cells develop into dendritic cells in human thymic stromal monolayers and thymic nodules." Journal of Immunology (Baltimore, Md. : 1950) 160, no. 7 (April 1998): 3290-3298.
    • Nair, SK, Boczkowski, D, Morse, M, Cumming, RI, Lyerly, HK, and Gilboa, E. "Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA." Nature Biotechnology 16, no. 4 (April 1998): 364-369.  Full Text
    • Morse, MA, and Lyerly, HK. "Immunotherapy of cancer using dendritic cells." Cytokines Cell Mol Ther 4, no. 1 (March 1998): 35-44. (Review)  Link to Item
    • Wong, C, Morse, M, and Nair, SK. "Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides." J Immunother 21, no. 1 (January 1998): 32-40.  Link to Item
    • Miralles, GD, Patel, DD, FernandezCasal, M, Whichard, LP, Morse, MA, and Smith, CA. "Extrathymic stem cells develop into dendritic cells in human thymic microenvironments in vitro." BLOOD 90, no. 10 (November 15, 1997): 3382-3382.  Link to Item
    • Morse, MA, Zhou, LJ, Tedder, TF, Lyerly, HK, and Smith, C. "Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy." Ann Surg 226, no. 1 (July 1997): 6-16.  Link to Item
    • Clary, BM, Coveney, EC, Philip, R, Blazer, DG, Morse, M, Gilboa, E, and Lyerly, HK. "Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells." Cancer Gene Ther 4, no. 2 (March 1997): 97-104.  Link to Item
    • Morse, MA, Lu, J, Gopalakrishnan, R, Peterson, LA, D'Ambrosio, SM, Wani, G, and Stoner, GD. "Mechanism of enhancement of esophageal tumorigenesis by 6-phenylhexyl isothiocyanate." Cancer Lett 112, no. 1 (January 15, 1997): 119-125.  Link to Item
    • Clary, BM, Coveney, EC, Blazer, DG, Philip, R, Philip, M, Morse, M, Gilboa, E, and Lyerly, HK. "Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system." J Immunother 20, no. 1 (January 1997): 26-37.  Link to Item
    • Morse, MA, and Garcia, VF. "Selective nonoperative management of pediatric blunt splenic trauma: risk for missed associated injuries." Journal of pediatric surgery 29, no. 1 (January 1994): 23-27. (Academic Article)
    • Morse, MA, and Rutlen, DL. "Influence of nitroglycerin on splanchnic capacity and splanchnic capacity-cardiac output relationship." J Appl Physiol (1985) 76, no. 1 (January 1994): 112-119.  Full Text  Link to Item
    • Morse, MA, Eklind, KI, Toussaint, M, Amin, SG, and Chung, FL. "Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats." Carcinogenesis 11, no. 10 (October 1990): 1819-1823. (Academic Article)
    • Morse, MA, Bell, L, and Rutlen, DL. "Influence of splanchnic intravascular volume changes on cardiac output during muscarinic receptor stimulation in the anaesthetized dog." Acta Physiol Scand 138, no. 3 (March 1990): 331-336.  Full Text  Link to Item

  • Other Articles

    • Hamilton, E, Blackwell, K, Hobeika, AC, Clay, TM, Broadwater, G, Ren, XR, Chen, W, Castro, H, Lehmann, F, Spector, N, Wei, J, Osada, T, Lyerly, HK, and Morse, MA. "Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion." J Transl Med 11 (2013): 82-.  Full Text  Link to Item
    • Hobeika, AC, Clay, TM, and Morse, MA. "Monitoring immunity to cancer vaccines." Enhancer - Biotherapy of Cancer 4, no. 2 (2006): 8-11.
    • Morse, MA, Lyerly, HK, and Clay, TM. "Immunotherapy of surgical malignancies: Commentary." Diseases of the Colon and Rectum 48, no. 1 (2005): 182--.
    • Morse, M, Clary, B, and Lyerly, HK. "Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery: Commentary." Journal of Surgical Oncology 82, no. 2 (2003): 131--.  Full Text
    • Lyerly, HK, Morse, MA, and Clay, TM. "Surrogate markers of effective anti-tumor immunity." Annals of Surgical Oncology 8, no. 3 (April 2001): 190-191.  Full Text
    • Morse, MA, Clay, TM, Hobeika, AC, Mosca, PJ, and Lyerly, HK. "Surrogate markers of response to cancer immunotherapy." Expert Opinion on Biological Therapy 1, no. 2 (March 2001): 153-158.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.